2016 IMS Recommendations on women’s midlife health and menopause hormone therapy

R. J. Baber, N. Panay & A. Fenton the IMS Writing Group

To cite this article: R. J. Baber, N. Panay & A. Fenton the IMS Writing Group (2016) 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy, Climacteric, 19:2, 109-150, DOI: 10.3109/13697137.2015.1129166

To link to this article: http://dx.doi.org/10.3109/13697137.2015.1129166

Published online: 12 Feb 2016.

Article views: 396

Submit your article to this journal

View related articles

View Crossmark data
RecommendaTions

2016 IMS Recommendations on women’s midlife health and menopause hormone therapy

R. J. Baber, N. Panay, A. Fenton and the IMS Writing Group

Abstract

The International Menopause Society (IMS) has produced these new 2016 recommendations on women’s midlife health and menopause hormone therapy (MHT) to help guide health-care professionals in optimizing their management of women in the menopause transition and beyond. The term MHT has been used to cover therapies including estrogens, progestogens and combined regimens. For the first time, the 2016 IMS recommendations now include grades of recommendations, levels of evidence and ‘good practice points’, in addition to section-specific references. Where possible, the recommendations are based on and linked to the evidence that supports them, unless good-quality evidence is absent. Particular attention has been paid to published evidence from 2013 onwards, the last time the IMS recommendations were updated. Databases have been extensively searched for relevant publications using key terms specific to each specialist area within menopause physiology and medicine. Information has also been drawn from international consensus statements published by bodies such as the IMS, the European Menopause and Andropause Society and the North American Menopause Society. The recommendations have been produced by experts derived mainly from the IMS, with the assistance of key collaborators where deemed advantageous. In preparing these international recommendations, experts have taken into account geographical variations in medical care, prevalence of diseases, and country-specific attitudes of the public, medical community and health authorities towards menopause management. The variation in availability and licensing of MHT and other products has also been considered.

Introduction

The International Menopause Society (IMS) is pleased to provide these new evidence-based recommendations on the use of menopausal hormone therapy (MHT). In the 3 years that have passed since publication of our 2013 Recommendations, new research into the health of midlife women and re-evaluation of existing data have allowed clinicians world-wide to gain more clarity into the role of MHT, not only in the alleviation of troublesome menopausal symptoms, but also in the prevention of diseases of aging. A key turning point in this process was the IMS-sponsored Global Consensus Meeting held in Paris in November 2012 and the subsequent publication of a concise Global Consensus Statement supported by major societies interested in the health and well-being of midlife women.

It is timely that these new, detailed 2016 IMS Recommendations have been published. The format of these Recommendations has changed since the 2013 publication. Each section now contains a brief summary of the key points of the topic and a summary of the way in which evidence used was identified and assessed. Importantly, these Recommendations now include grades of recommendations, levels of evidence and some practical ‘Good practice points’. It is important to note that the evidence supporting these recommendations is derived from research largely performed on women living in Western countries. This may not necessarily be directly applicable to other women. Of course, references are included.

Throughout the Recommendations, the term MHT has been used to cover therapies including estrogens, progestogens and combined therapies. The IMS is aware of the geographical variations related to different priorities of medical care, different prevalence of diseases, and country-specific attitudes of the public, the medical community and health authorities toward menopause management, different availability and licensing of products, all of which may impact on MHT. These Recommendations and the subsequent key messages therefore give a simple overview that serves as a common platform on issues related to the various aspects of hormone therapy, which
could be easily adapted and modified according to local needs.

Methodology

This guideline was produced by a body of experts derived primarily but not exclusively from the IMS. Medline, PubMed, the Cochrane register of controlled trials and other databases were extensively searched for relevant publications using key terms specific to each specialist area within menopause physiology and medicine. Information was also drawn from international consensus statements published by bodies such as the IMS, the European Menopause and Andropause Society (EMAS) and the North American Menopause Society (NAMS). Particular attention was paid by the authors to the new publications from 2013 onwards which was the last time the IMS Recommendations were updated.

The definitions of types of evidence used in this guideline are detailed in the Governance advice No. 1 of the Royal College of Obstetricians and Gynaecologists1. Table 1 shows the definitions for levels of evidence (<1++> to <4->) and grades of recommendations ([A], [B], [C] or [D]) used when assessing the value of data and strength of recommendations in each section. Where possible, recommendations are based on and linked to the evidence that supports them unless good-quality evidence is absent. Areas where advice has been issued in the absence of good evidence, but based on extensive experience, are annotated as good practice points, indicated by ✔.

The authors have strived for a consistent style of assessment and reporting through the issuing of explicit guidelines to the section authors at the start of the guideline process. Nonetheless, given the multi-author nature of this document, there will inevitably be some variation in the consistency with which the data have been reported and interpreted.

### IMS governing principles on MHT

- MHT remains the most effective therapy for vasomotor symptoms and urogenital atrophy.
- Other menopause-related complaints, such as joint and muscle pains, mood swings, sleep disturbances and sexual dysfunction (including reduced libido) may improve during MHT.
- Quality of life and sexual function may also improve.
- The administration of individualized MHT (including androgenic preparations when appropriate) may improve both sexuality and overall quality of life.
- Consideration of MHT should be part of an overall strategy including lifestyle recommendations regarding diet, exercise, smoking cessation and safe levels of alcohol consumption for maintaining the health of peri- and postmenopausal women.
- MHT must be individualized and tailored according to symptoms and the need for prevention, as well as personal and family history, results of relevant investigations, the woman’s preferences and expectations.
- The risks and benefits of MHT differ for women during the menopause transition compared to those for older women.

### Table 1. Levels of evidence and Grades of recommendations (taken from the Royal College of Obstetricians and Gynaecologists UK Green Top Guidelines).

<table>
<thead>
<tr>
<th>Classification of evidence levels</th>
<th>Grades of recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;1+++</td>
<td>[A] At least one meta-analysis, systematic review or randomized controlled trial rated as 1++, and directly applicable to the target population; or a systematic review of randomized controlled trials or a body of evidence consisting principally of studies rated as 1+, directly applicable to the target population and demonstrating overall consistency of results</td>
</tr>
<tr>
<td>&lt;1+</td>
<td>[B] A body of evidence including studies rated as 2++ directly applicable to the target population, and demonstrating overall consistency of results; or extrapolated evidence from studies rated as 1++ or 1+</td>
</tr>
<tr>
<td>&lt;1&lt;</td>
<td></td>
</tr>
<tr>
<td>&lt;1&lt;</td>
<td></td>
</tr>
<tr>
<td>&lt;2+</td>
<td></td>
</tr>
<tr>
<td>&lt;2&lt;</td>
<td></td>
</tr>
<tr>
<td>&lt;3</td>
<td></td>
</tr>
<tr>
<td>&lt;4</td>
<td></td>
</tr>
</tbody>
</table>

✔ **Good practice point:** Recommended best practice based on the clinical experience of the guideline development group.
MHT includes a wide range of hormonal products and routes of administration, with potentially different risks and benefits. Thus, the term ‘class effect’ is confusing and inappropriate. However, evidence regarding differences in risks and benefits between different products is limited.

Women experiencing a spontaneous or iatrogenic menopause before the age of 45 years and particularly before 40 years are at higher risk for cardiovascular disease and osteoporosis and may be at increased risk of affective disorders and dementia. MHT may reduce symptoms and preserve bone density and is advised at least until the average age of menopause.

Counselling should convey the benefits and risks of MHT in clear and comprehensible terms, e.g. as absolute numbers rather than, or in addition to, percentage changes from baseline expressed as a relative risk. This allows a woman and her physician to make a well-informed decision about MHT. Written information about risks and benefits as well as decision aids may be useful.

MHT should not be recommended without a clear indication for its use, i.e. significant symptoms or physical effects of estrogen deficiency.

Women taking MHT should have at least an annual consultation to include a physical examination, update of medical and family history, relevant laboratory and imaging investigations, a discussion on lifestyle, and strategies to prevent or reduce chronic disease. There is currently no indication for increased mammographic or cervical smear screening.

There are no reasons to place mandatory limitations on the duration of MHT. Data from the WHI trial and other studies support safe use for at least 5 years in healthy women initiating treatment before age 60.

Whether or not to continue therapy should be decided at the discretion of the well-informed woman and her health professional, dependent upon the specific goals and an objective estimation of ongoing individual benefits and risks.

The dosage should be titrated to the lowest effective dose.

Lower doses of MHT than previously used may reduce symptoms sufficiently and maintain quality of life for many women. However, long-term data on lower doses regarding fracture or cancer risks and cardiovascular implications are still lacking.

Midlife body changes

Weight gain at midlife is often attributed to hormonal changes at menopause. However, both cross-sectional and longitudinal studies have consistently shown this not to be the case. The steady weight gain, of about 0.5 kg per year, seen in women at midlife is associated with age and environmental factors, not menopause. Variables associated with a greater likelihood of obesity in women at midlife include urbanization, lower level of education, inactivity, higher parity, family history of obesity and marriage at earlier age. Disruption of the circadian rhythm by shift work and sleep deprivation also contributes to weight gain. The relationship between depression and midlife weight gain is bidirectional.

The change in the hormonal milieu at menopause is associated with significant increases in waist circumference and central abdominal fat. Increased waist circumference occurs in relation to final menstrual period and significant increases in central abdominal fat have been seen in longitudinal studies of Caucasian and Asian women. Total mass, percentage fat mass, truncal fat mass and visceral fat also increase in non-obese women across the menopausal transition. The redistribution of fat to the abdomen results in a transition from a gynoid to an android pattern of fat distribution. Studies using a range of radiological modalities have shown that postmenopausal women have greater amounts of intra-abdominal fat compared to premenopausal women. Waist circumference represents both subcutaneous and visceral adipose tissue depot size and correlates closely with cardiovascular disease risk. In women, it is also closely associated with dyslipidemia. Animal models show that estrogen depletion favors central abdominal fat accumulation and that this is ameliorated by estrogen therapy.

Governing principles for managing midlife body changes

The primary approach to minimize weight gain at midlife is caloric restriction and maintenance of physical activity.

Management of factors associated with weight gain, such as depression, is important. If depression requires pharmacotherapy, medications associated with weight gain commonly used such as clozapine, imipramine, and amitriptyline should be avoided if possible.

Most randomized, controlled trials (RCTs) show a reduction in central adiposity with estrogen therapy. In a subsample of participants in the Women’s Health Initiative (WHI) estrogen plus progestin
therapy (E+P) study, the E+P intervention at 3 years significantly helped to maintain lean body mass and prevented a shift toward android fat distribution. The effects of exogenous estrogen are generally favorable in terms of body composition; however, the route of estrogen delivery may have subtle, but differing effects. Oral estrogen has been associated with a small but significant increase in fat mass and a decrease in lean mass, whereas lean body mass and fat mass are unaffected by transdermal estradiol. Neither route appears to alter visceral fat mass. The different effects of oral versus transdermal estrogen may relate to the effects of route of administration on growth factors and substrate oxidation.

Summary

Weight management and prevention of weight gain are essential components in the care of postmenopausal women. Optimizing body weight should be considered early in the perimenopause to safeguard the quality of life of women. The primary approach to weight management should be encouragement of a healthy diet and physical activity. Contrary to widespread belief, menopausal hormone therapy is not associated with weight gain and may ameliorate perimenopausal accretion of abdominal fat.

Key messages

- An absolute increase in weight at midlife is not attributable to the menopause.
- The hormonal changes that accompany menopause are associated with increases in total body fat and abdominal fat, even in lean women.
- Maintenance of a healthy diet and avoidance of caloric excess combined with physical activity are important components of weight management.
- Menopausal abdominal fat accumulation is ameliorated by estrogen therapy, with a reduction in overall fat mass, improved insulin sensitivity and a lower rate of development of type 2 diabetes.

Diagnosis of menopause

Information is mainly derived from consensus rather than data and therefore statements are mainly supported by Good Practice Points.

Definition

Menopause is defined as the final menstrual period. Menopause is a retrospective clinical diagnosis, as the final menstrual period can only be defined if followed by 12 months of amenorrhea.

Menopause before the age of 40 years is considered to be premature, whether occurring naturally or as a result of surgery or some other intervention (e.g. chemotherapy). The clinical implications of menopause before age 40 are different from menopause after age 40. Treatment of premature menopause is typically considered more critical (see section on Premature ovarian insufficiency).

Menopause is a natural and inevitable event that happens on average at age 51 years in white Caucasians with ethnic and regional variations.

Stages of Reproductive Aging Workshop + 10

Accurate staging of reproductive aging is important from a clinical and research perspective. The gold-standard criteria for staging reproductive aging were defined by the Stages of Reproductive Aging Workshop + 10 (STRAW + 10) see Figure 1.

Antral follicle count, follicle stimulating hormone (FSH), anti-Müllerian hormone (AMH), and inhibin B are included as supplementary criteria. They are of greater importance to the fertility specialist and are not essential in the diagnosis of menopause. Specific cut-off values for AMH and inhibin B were not proposed given the lack of international standardization for those hormonal assays.

The criteria also identify the stages at which vasomotor symptoms (VMS) and urogenital atrophy are evident, although menopausal symptoms are not used in determining stage.

Standard terminology is used to identify three broad stages of reproductive aging (Reproductive, Menopausal Transition, and Postmenopause), each broken down further into Early, Peak (reproductive stage only) and Late stages. Altogether, there are a total of ten specific stages, labeled from −5 to +2. Stage −1, for example, corresponds to the late stage of the menopausal transition, with the principal criterion of an interval of amenorrhea of >60 days and other supportive criteria such as FSH >25 IU/l (see Figure 1).

STRAW + 10 guidelines recommend waiting at least 3 months after surgery to assess supportive endocrine criteria, because evidence suggests that FSH levels rise temporarily following pelvic surgery.

Although VMS are the cardinal symptoms of menopause, they should not be used to stage women because VMS are reported in the reproductive stage and may last for many years after the final menstrual period.

STRAW +10 was sponsored by the National Institute on Aging, the Office of Research on Women’s Health, NAMS, the American Society for Reproductive Medicine
ASRM), the IMS, and the Endocrine Society. The criteria for STRAW + 10 were the result of a 2-day in-person meeting of international experts hosted at the 2011 Annual Meeting of NAMS1. The criteria built on original menstrual cycle criteria from the 2001 Stages of Reproductive Aging Workshop (STRAW)5 and the ReSTAGE Collaboration, which validated the criteria based on empirical analyses of four cohort studies6–9.

**Key messages**

- Current data indicate that the STRAW + 10 criteria apply to most, but not all women.
- The criteria cannot be used in women with polycystic ovarian syndrome and premature ovarian insufficiency and those who have had endometrial ablation or removal of a single ovary and/or hysterectomy. In such women, the supportive criteria should be used to determine reproductive stage.
- With the availability of new multi-ethnic studies9–14, STRAW + 10 provided support for the generalizability of RESTAGE to ethnically diverse women, as well as to smokers and obese women. [B]
- STRAW + 10 principally relies on changes in bleeding patterns as staging criteria with the last menstrual period as the pivotal point. [✓]

**Premature ovarian insufficiency**

**Background and introduction**

Premature ovarian insufficiency (POI) (also known as premature menopause) is defined as primary hypogonadism before the age of 40 years in women with a normal karyotype who previously had normal menstrual cycles. It is characterized by typical menopausal symptoms and signs, oligomenorrhea or amenorrhea and FSH >40 IU/l.

The diagnosis of POI should only be confirmed after a minimum of two elevated FSH test results (>40 IU/l) at least 4–6 weeks apart. The incidence of spontaneous POI is 1% of women under the age of 40 years and 0.1% of women under the age of 30 years1. <2++>

The incidence of iatrogenic POI may be growing due to increasing survival rates following chemo- and radiotherapy.

![Figure 1.](image-url)
Women with POI are now recognized to be at increased risk for premature morbidity and mortality. They have impaired endothelial function, ischemic heart disease, and a higher incidence of osteoporotic fractures, impaired cognition, and diminished sexual well-being. <2+>

**Etiological factors**

POI may be either primary or secondary. In the majority of cases of primary POI, the cause is unknown. The causes of POI are shown in Table 2. <1+++>

Karyotype methodology has detected monosomy X, mosaicism, X chromosome deletions and rearrangements, X-autosome translocations, and isochromosomes in women with POI. <1+++>

Candidate gene studies have detected a number of single gene perturbations predisposing to POI in at least one population. A meta-analysis of gene variations and POI showed that bone morphogenetic protein 15 538A (BMP 15 538A), Fragile X mental retardation 1 (FMR1) premutation on the X chromosome and inhibin alpha 769 (INHA 769) (in Asians alone) may indicate susceptibility to POI. <1+++>

Other likely candidate genes include progesterone receptor membrane component 1 (PGRMC1), growth differentiation factor 9 (GDF9) and newborm ovary homebox gene (NOBOX). <1+++>

Studies performed in Serbian women showed that estrogen receptor (ER) α gene polymorphism is not associated with POI. Ethnically distinct populations may show differences in gene-regulating pathways and genes causing POI, like in Han Chinese vs. Serbian women for tested loci: 8q22.3, HK3, BRSK1. <2+>

Whole genome approaches, e.g. genome wide association studies (GWAS), are currently being used to reveal loci not predicted by candidate genes.

Polyglandular autoimmune diseases can be found in some women with POI. Autoimmune hypothyroidism, diabetes mellitus, adrenal insufficiency and hypoparathyroidism occur more frequently in women with POI compared to background rates. <2+>

**Management**

Management should include detailed history taking including family history, vaginal examination, hormone analysis, karyotyping, fragile X, thyroid and adrenal antibody assays and ultrasound scanning (Table 3).

Information on hot flushes, vaginal dryness, lack of libido, arthralgia, loss of concentration, insomnia and fertility issues should be obtained in a sensitive and caring manner.

<table>
<thead>
<tr>
<th>Table 2. Known causes of premature ovarian insufficiency.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary</strong></td>
</tr>
<tr>
<td>Genetic chromosome abnormalities</td>
</tr>
<tr>
<td>FMR1 premutations</td>
</tr>
<tr>
<td>other gene candidates</td>
</tr>
<tr>
<td>Enzyme deficiencies</td>
</tr>
<tr>
<td>Autoimmune diseases</td>
</tr>
<tr>
<td><strong>Secondary</strong></td>
</tr>
<tr>
<td>Chemotherapy and radiotherapy</td>
</tr>
<tr>
<td>Bilateral oophorectomy or surgical menopause</td>
</tr>
<tr>
<td>Hysterectomy without oophorectomy/uterine artery embolization</td>
</tr>
<tr>
<td><strong>Infections</strong></td>
</tr>
</tbody>
</table>

The diagnostic usefulness of ovarian biopsy outside the context of a research setting is unproven.

**Therapeutic options**

Women with POI should receive hormonal treatment after exclusion of contraindications; they usually need higher doses of estrogens compared to women over 40 years old. The recommended estrogen doses are: 17β-estradiol 2 mg/day or 1.25 mg conjugated equine estrogen (CEE) or transdermal estradiol 75–100 μg/day or 10 μg ethinylestradiol. The aim is to achieve the typical mean serum estradiol levels of approximately 100 pg/ml (400 pmol/l) in regularly menstruating women. Micronized progesterone can be administered as a cyclic regimen (200 mg for 12 days each month) or as a continuous regimen of 100 mg per day, typically >2 years post final menstrual period.

Combined estrogen/progestogen contraceptive pills (COCs) may be used continuously until the expected time of the menopause but data are lacking regarding impact on bone and cardiovascular disease. Data from small randomized trials of surrogate markers suggest that bone mineralization and metabolic effects are more favorable with MHT compared to COCs. <1-->

Hormone therapy is not contraceptive unless estrogen is combined with a levonorgestrel intrauterine system; it may therefore be more practical for the COC to be used for the first few years following diagnosis of POI in those wishing to avoid pregnancy.
In women with low libido, especially in oophorectomized women, testosterone gels or patches could be prescribed; however, due to the lack of licensed female options, down titration of male products may be necessary (see section on Androgens).

Women with POI have a 5–15% chance of spontaneous conception after confirmation of diagnosis. Inappropriate follicular luteinization is the most common pathophysiological mechanism that prevents ovulation and pregnancy.

Exogenous estrogens have beneficial effects on ovulation and fertility. However, ovulation only seems to occur in women whose serum FSH concentrations are suppressed to below 15 IU/l. Gonadotropin therapy is ineffective in achieving ovulation and gonadotropin releasing hormone agonists do not improve ovulatory rates.

Donor oocyte in vitro fertilization is a successful treatment choice for women with POI.

In women undergoing chemotherapy or radiotherapy, in vitro fertilization (IVF) with embryo freezing prior to treatment offers the highest likelihood of a future pregnancy.

Freezing of mature eggs is less successful than embryo freezing.

Cryopreservation and transplantation of fresh ovarian tissue are leading to an increasing number of successful pregnancies.

A meta-analysis (24 articles from 1980 to 2013) of ovarian transposition in women with cancers has shown that ovarian transposition is associated with significant preservation of ovarian function.

Key messages

- POI is defined as primary hypogonadism in women younger than 40 years who previously had menstrual cycles.
- The diagnosis of POI is confirmed by the finding of FSH levels >40 IU/l on two occasions 4–6 weeks apart.
- POI should be effectively treated to prevent an increase in the risk of cardiovascular disease, osteoporosis, cognitive decline, dementia and Parkinsonism.
- Investigation of POI should include hormone analysis, screening for autoimmune causes, karyotyping, fragile X premutation testing and pelvic ultrasound.
- It is important to inform the woman of the diagnosis with empathy in a sensitive and caring manner. Women must be provided with adequate information and counseling.
- The mainstay of treatment is hormone replacement with estrogen, progesterone and possibly testosterone which needs to be continued at least until the average age of the natural menopause.
- Hormone treatment with COC or MHT can induce ovulation in POI patients if FSH levels are suppressed.
- MHT should not be regarded as being contraceptive.
- Ovarian stimulation with drugs such as clomiphene citrate and gonadotropin therapy should not be routinely used as they have no proven benefit.
- IVF with donor oocytes/embryos has a high success rate but is not acceptable to all women with POI.

Lifestyle, diet and exercise

The public health approach to lifestyle promotion requires a multidisciplinary approach, starting from schools through to work places, involving the food and advertising industry, as well as medical insurers and health authorities. A new paradigm in doctor–patient relations is required, where the doctor becomes more of an advisor and the patient takes responsibility for his/her own health.

Improved metabolic profile, balance, muscle strength, cognition and quality of life are observed in physically active women. Heart events, stroke, fractures and breast and colon cancers are significantly less frequent. The benefits of exercise far outweigh possible adverse consequences: the more, the better, but too much may cause harm.

Obesity (body mass index >30 kg/m²) affects over 20% of the population in many parts of the world and is becoming an increasing problem in the lower socioeconomic sectors and also among children. It can be associated with insulin resistance and thus increases not only a woman’s risk of cardiovascular disease and diabetes, but also increases the risk for breast, colon and endometrial cancers.

Key messages

- Regular exercise is advised to reduce cardiovascular and total mortality.
- Optimal exercise prescription is at least 150 minutes of moderate-intensity exercise per week. Two additional weekly sessions of resistance exercise may provide further benefit.
The recommended intensity of aerobic activity should take into account the older adult’s aerobic fitness.

Weight loss of only 5–10% is sufficient to improve many of the abnormalities associated with the insulin resistance syndrome. [B]

The basic components of a healthy diet are: several servings/day of fruits and vegetables, whole grain fibers, fish twice per week, and low total fat (but the use of olive oil is recommended). Consumption of salt should be limited and the daily amount of alcohol should not exceed 30 g for men and 20 g for women. [A]

Smoking should be avoided. [A]

Lifestyle modifications include socializing and being physically/mentally active. [A]

Urogynecology

The female genital and lower urinary tracts share a common embryological origin, arising from the urogenital sinus and both are sensitive to the effects of female sex steroid hormones throughout life. Estrogen is known to have an important role in the function of the lower urinary tract and estrogen and progesterone receptors have been demonstrated in the vagina, urethra, bladder and pelvic floor musculature. Consequently, exogenous estrogen therapy may be useful in the management of pelvic floor dysfunction.

Urinary incontinence

The role of systemic estrogens in the management of postmenopausal women with lower urinary tract symptoms has been investigated in three large epidemiological studies examining the use of combined estrogen/progestogen and estrogen-only systemic hormone replacement therapy. In all of these trials, systemic estrogen replacement therapy was found to increase the risk of developing both stress and urgency urinary incontinence, and, in those women who complained of urinary incontinence at baseline, the symptoms were found to deteriorate. This was also reflected in deterioration in quality of life.

The most recent meta-analysis of the effect of estrogen therapy on the lower urinary tract has been performed by the Cochrane group and identified 33 trials, including 19,313 incontinent women (1,262 involved in trials of local administration) of whom 9,417 received estrogen therapy. Systemic administration (of unopposed oral estrogens – synthetic and CEE) resulted in worse incontinence than placebo (relative risk (RR) 1.32; 95% confidence interval (CI) 1.17–1.48), although this is heavily influenced by the size of the WHI study. When considering combination therapy, there was a similar worsening effect on incontinence when compared to placebo (RR 1.11; 95% CI 1.04–1.18). There was some evidence suggesting that the use of local estrogen therapy may improve incontinence (RR 0.74; 95% CI 0.64–0.86) and overall there were one to two fewer voids in 24 h and less frequency and urgency.

Overactive bladder

Lifestyle changes and bladder retraining have been shown to be effective for overactive bladder symptoms. In a review of ten randomized, placebo-controlled trials, systemic estrogen was not found to be superior to placebo when considering symptoms of urgency, frequency and nocturia, although vaginal estrogen administration was found to be superior to placebo for the symptom of urgency. There is also evidence to suggest that combination therapy with an antimuscarinic drug may be beneficial and the current guidelines from the International Consultation on Incontinence (ICI) also suggest that local estrogen therapy may have a role.

Stress urinary incontinence

Data show that all women complaining of stress urinary incontinence will benefit from pelvic floor muscle training in the first instance. Duloxetine may work synergistically with conservative therapy, although some women will ultimately require surgery, and retropubic and trans-obturator tapes are currently the most popular procedures. A review of eight controlled and 14 uncontrolled prospective trials concluded that estrogen therapy was not an efficacious treatment for stress incontinence but may be useful for symptoms of urgency and frequency. This is supported by the findings of the ICI.

Estrogens in the management of recurrent urinary tract infection

Estrogen therapy has been shown to decrease vaginal pH and reverse the microbiological changes that occur in the vagina following the menopause and has been shown to be useful in the prevention of recurrent urinary tract infections. A Cochrane review has investigated the role of estrogens in the management of recurrent lower urinary tract infections in nine studies including 3,345 women. Oral estrogens were found to be ineffective (RR 1.08; 95% CI 0.88–1.33). Two
small studies found that vaginal estrogens reduced the number of infections when compared to placebo (RR 0.25; 95% CI 0.13–0.50; and RR 0.64; 95% CI 0.47–0.86, respectively)\(^\text{15}\). <1+>

**Urogenital atrophy**

Whilst the evidence supporting the use of estrogens in lower urinary tract dysfunction remains controversial, there are considerable data to support their use in urogenital atrophy\(^\text{16}\) and the vaginal route of administration correlates with better symptom relief by improving vaginal dryness, pruritis and dyspareunia, and greater improvement in cytological findings\(^\text{17}\). The most recent meta-analysis of intravaginal estrogen treatment in the management of urogenital atrophy was reported by the Cochrane group in 2003\(^\text{18}\).

Sixteen trials with 2129 women were included and intravaginal estrogen was found to be superior to placebo in terms of efficacy, although there were no differences between types of formulation. Fourteen trials compared safety between the different vaginal preparations and found a higher risk of endometrial stimulation with conjugated equine estrogens as compared to estradiol. <1+>

**Key messages**

- Symptoms such as vaginal dryness, soreness, dyspareunia, urinary frequency, nocturia and urgency are extremely common in postmenopausal women.
- Incontinence in women increases in prevalence with age.
- There is a wide variation in symptoms and signs of urogenital aging.
- The loss of lubrication and hormonal changes may lead to sexual dysfunction. Treatment of this condition improves quality of life, not only for the woman but also for her partner.
- Urogenital symptoms respond well to estrogens. [A]
- Long-term treatment is often required as symptoms can recur on cessation of therapy. Systemic risks have not been identified with local low-potency/low-dose estrogens. [B]
- Use of systemic MHT does not seem to prevent urinary incontinence and is not preferable to low-dose local estrogens in the management of urogenital atrophy or recurrent lower urinary tract infections. [B]
- Lifestyle changes and bladder retraining are recommended as first-line therapy for overactive bladder symptoms. [x]
- Antimuscarinic drugs, combined with local estrogens, constitute first-line medical treatment in postmenopausal women with symptoms suggestive of an overactive bladder. [A]
- All women complaining of stress urinary incontinence will benefit from pelvic floor muscle training in the first instance. [x]
- Duloxetine may work synergistically with conservative therapy. However, some women will ultimately undergo surgery, and retropubic and transobturator tapes are currently the most popular procedures.
- There is currently no role for systemic estrogen therapy in women with pure stress urinary incontinence. [A]

**Postmenopausal osteoporosis**

Osteoporosis is a systemic skeletal disease characterized by diminished bone strength with the risk of sustaining a fracture when falling from own body height (fragility fracture). Bone strength is determined by a combination of bone density and microarchitectural integrity. Postmenopausal osteoporosis results from a failure to attain peak bone density, accelerated bone loss after menopause, age-related bone loss or a combination of factors. Accelerated postmenopausal bone loss is induced by estrogen deprivation.

Although skeletal health is a function of genetic predisposition, it can be modified by lifestyle factors such as diet, weight-bearing exercise and the avoidance of bone-toxic substances\(^\text{1}\), <1+>

Hip fracture is responsible for the largest proportion of the financial burden of osteoporosis to health-care systems but other osteoporosis-related fractures, particularly vertebral fractures, cause considerable morbidity\(^\text{2}\), <1+>

**Diagnosis and assessment**

The diagnosis of osteoporosis is based on assessment of bone mineral density (BMD) by dual X-ray absorptiometry (DXA). The value obtained is compared to peak bone density and expressed as the T-score. Osteoporosis is defined as a T-score \(\leq -2.5\) or the presence of a fragility fracture. Assessment of BMD is not a cost-effective population screening tool but is best applied on a selective basis, based on age and other risk factors such as a personal or family history of fractures, history of amenorrhea, primary ovarian insufficiency, low body mass, diet, smoking, alcohol abuse, the use of bone toxic medication and rheumatoid arthritis\(^\text{3}\). <1+>

The 10-year probability of fracture in an individual can be estimated
using a model that integrates various risk factors for fracture, such as the FRAX® model developed by the World Health Organization, which is available online at www.sheffield.ac.uk/FRAX/. It should be noted that the sensitivity of the FRAX model in early menopause has been questioned as being lower compared to sensitivity in older women4. An appropriate assessment of prevalent fractures and secondary causes of osteoporosis should precede any therapeutic decisions.

Treatment

The goal of osteoporosis treatment is the prevention of fracture. Choice of therapy should be based on a balance of effectiveness, risk and cost. Intervention thresholds for therapy can be based on 10-year fracture probability but will be country-specific. Alternatively, treatment can be given to all patients with a fragility fracture or a T-score of ≤−2.5 (osteoporosis), or a T-score of ≤−1.0 > −2.5 (osteopenia) with additional risk factors. Monitoring of therapy by serial DXA should be interpreted with caution and take into account the site monitored, time interval, drug-specific expectations and the value of least significant change as calculated for the specific device and operator.

Therapeutic options

Menopausal hormone therapy

MHT decreases the incidence of all fractures, including vertebral and hip fractures, even in women not at high risk of fracture5. MHT is the only therapy available with proven efficacy of fracture reduction in patients with osteopenia.

Although MHT prevents fractures at any age after the menopause, age at the initiation of MHT is important6. In the age group 50–60 years or within 10 years after menopause, the benefits of MHT are most likely to outweigh any risk and can be considered as first-line therapy7. Initiation of MHT in the age group 60–70 years requires individually calculated benefit/risk, consideration of other available drugs and the lowest effective dose8. MHT should not be initiated after age 70 years. There is no mandatory time limit for duration of MHT provided that it is consistent with treatment goals. This is important as the protective effect of MHT on BMD declines after cessation of therapy at an unpredictable rate, although some degree of fracture protection may remain after cessation of MHT9. Therefore, the continuation of MHT for the sole purpose of the prevention of fractures should take into account the risk of fracture as well as other possible long-term benefits and risks. Evidence for the fracture-protective effect of MHT is limited to standard dosages of CEE and medroxyprogesterone acetate (MPA), given by the oral route. Evidence for protection against loss of BMD is available for lower than standard doses in oral (CEE and 17β-estradiol) and transdermal (17β-estradiol) administration10.

Tibolone, a synthetic preparation metabolized to molecules that have affinity for the estrogen, progesterone and androgen receptors prevented vertebral and non-vertebral fractures in a RCT11.

In women with a uterus, the stimulatory effects of CEE on the endometrium can be opposed by the selective estrogen receptor modulator (SERM) bazedoxifene. This combination, also known as tissue selective estrogen complex, has been shown to prevent the bone loss associated with menopause but the effect on fracture reduction has not been explored12.

Calcium and vitamin D

Postmenopausal women need a dietary reference intake (DRI) of 1000–1500 mg of elemental calcium. Calcium supplementation should be restricted to bridge the shortfall between dietary intake and the DRI and to patients being treated for high fracture risk13. Routine dietary calcium supplementation cannot be justified in terms of efficacy, safety and health economics. Excessive calcium supplementation may be associated with increased cardiovascular risk, renal calculi and constipation14.

The DRI for vitamin D is 800–1000 IU in the postmenopausal period. As the major source of vitamin D is dependent on sunlight exposure, the need for supplementation will vary. Measuring the blood 25-hydroxyvitamin D level may be helpful in selected individuals15. Vitamin D supplementation has been shown independently to lower the risk of fracture and of falling in elderly patients16.

Bisphosphonates

The bisphosphonates are potent inhibitors of bone resorption with proven efficacy in the prevention of vertebral and hip fractures17,18. Some safety issues are relevant. An association has been suggested between atypical femur shaft fractures and over-suppression of bone turnover in patients exposed to bisphosphonates for longer than 3–5 years. A drug-free period may be considered after 3 years of intravenous zoledronic acid or 5 years of oral alendronate therapy, provided that BMD increases to a DXA-derived T-score of >−2.5 and in the...
absence of any fracture<sup>19</sup>. Bisphosphonate-related osteonecrosis of the jaw is a rare complication and generally is only a risk when dosages greater than that recommended for fracture prevention are used<sup>20</sup>. There is no evidence that bisphosphonates prevent fractures in osteopenic patients.

**Selective estrogen receptor modulators**

The SERMs, raloxifene and bazedoxifene, reduce vertebral fractures in postmenopausal women with or without prevalent vertebral fractures<sup>21</sup>. Bazedoxifene prevents hip fracture in a select group of women at high risk of hip fracture<sup>22</sup>. Raloxifene prevents ER-positive breast cancer in osteoporotic women. The SERMs do not alleviate vasomotor symptoms associated with menopause.

**Parathyroid hormone**

Parathyroid hormone (PTH) is an anabolic agent that significantly reduces risk of vertebral fractures by stimulation of bone formation<sup>23</sup>. PTH is indicated for severe cases of osteoporosis or in patients who fracture while on other forms of therapy. PTH is given as a daily subcutaneous injection for a maximum of 18 months. After this period, the use of an antiresorptive agent must be considered. Use of PTH is limited by the cost being much higher than that of other available agents. Prior treatment with a bisphosphonate blunts the effect of subsequent PTH.

**Strontium ranelate**

Treatment with strontium ranelate significantly reduces the risk of vertebral and non-vertebral fractures in osteoporotic patients, irrespective of the presence of a fracture or age<sup>24</sup>. Recent concerns about cardiovascular safety have limited the use of strontium ranelate to cases of severe osteoporosis in patients at low risk of cardiovascular disease<sup>25</sup>. Strontium ranelate to cases of severe osteoporosis in patients with or without prevalent vertebral fractures<sup>21</sup>. Bazedoxifene prevents hip fracture in a select group of women at high risk of hip fracture<sup>22</sup>. Raloxifene prevents ER-positive breast cancer in osteoporotic women. The SERMs do not alleviate vasomotor symptoms associated with menopause.

**Denosumab**

Denosumab is a human monoclonal antibody to the receptor activator of nuclear factor-kappa B ligand (RANKL). At a dose of 60 mg subcutaneously 6-monthly, denosumab significantly reduces the risk of vertebral, non-vertebral and hip fractures<sup>26</sup>. Denosumab is generally safe and well tolerated.

**Key messages**

- Osteoporosis is a systemic skeletal disease characterized by diminished bone strength with the risk of sustaining a fracture when falling from own body height.
- Osteoporosis is defined as a DXA-derived T-score ≤ −2.5 or the presence of a fragility fracture.
- The 10-year probability of fracture in an individual can be estimated using a model that integrates various risk factors for fracture, such as the FRAX® model. Intervention thresholds for therapy can be based on 10-year fracture probability but will be country-specific.
- Alternatively, treatment can be given to all patients with a fragility fracture or a T-score of ≤ −2.5 (osteoporosis), or a T-score of < −1.0 > −2.5 (osteopenia) with additional risk factors.
- An appropriate assessment of prevalent fractures and secondary causes of osteoporosis should precede any therapeutic decisions.
- Lifestyle changes should be part of treatment strategy.
- Choice of pharmacological therapy should be based on a balance of effectiveness, risk and cost.
- MHT is the most appropriate therapy for fracture prevention in the early menopause.

**Skin, cartilage, connective tissues**

The effects of estrogen in bone are well characterized but data on the impact of estrogen on cartilage, skin and connective tissues have been slower to emerge.

**Cartilage**

Although no clear association has been found between lifetime estrogen exposure and the risk of osteoarthritis, generalized muscle and joint aches are among the commonest symptoms experienced by women at menopause<sup>1</sup>. Intervertebral discs are thinner after menopause and women show greater increases in the prevalence and incidence of osteoarthritis when compared to men. Furthermore, arthritis in women is more likely to be progressive and symptomatic.

Estrogen receptors ERα and ERβ have both been identified in chondrocytes and recent studies have also demonstrated estrogen receptors in synoviocytes. Several animal and pre-clinical studies have demonstrated protective effects on the cartilage from the use of estrogen<sup>2</sup>. Cartilage degradation has been shown to be less in women taking the SERM levormeloxifene or MHT<sup>3</sup>. The WHI has also demonstrated a 45% reduction in total joint surgery among women taking MHT compared to placebo<sup>4</sup>.
Skin

Estrogen receptors have been detected in many skin elements including keratinocytes, melanocytes, fibroblasts, hair follicles and sebaceous glands so it is likely that the withdrawal of estrogen at menopause will have measurable effects on skin health. Studies have shown that after menopause skin thins and there is a loss of viscoelasticity. Skin surface texture, waterholding capacity, collagen content of the dermis and viscoelasticity have shown improvement with the use of estrogen^5,6. <1+>

Ligaments and tendons

The effect of estrogen on the function and health of ligaments and tendons is not fully elucidated. Lower tendon stiffness, trends towards higher fibril density and higher collagen turnover have been described in women on MHT^7. <1+>

Key messages

- Estrogen has an effect on connective tissue throughout the whole body. [A]
- The marked predominance of polyarticular osteoarthritis in women and, in particular, the marked increase of osteoarthritis in women after the menopause suggests that female sex steroids are important for cartilage homeostasis. [B]
- Cartilage degradation and the need for joint replacement surgery are reduced among users of MHT. [A]
- Menopause is associated with a number of changes in skin health that may be reduced with the use of MHT or topical estrogen therapy. [A]

Cardiovascular disease

Cardiovascular disease is the principal cause of morbidity and mortality in postmenopausal women. Major primary prevention measures are smoking cessation, weight loss, blood pressure reduction, regular aerobic exercise and diabetes and lipid control^1. <1-> Primary prevention strategies which are effective in men, namely use of aspirin and statins, do not afford a protective effect for coronary disease, cardiovascular mortality or all-cause mortality in women^2. <1++>

MHT has the potential for improving the cardiovascular risk profile through its beneficial effects on vascular function, lipid levels and glucose metabolism; MHT has also been shown to reduce the incidence of new-onset diabetes mellitus^2. <1+>

There is strong and consistent evidence that estrogen therapy may be cardioprotective if started around the time of menopause (often referred to as the ‘window of opportunity’ or ‘timing’ hypothesis)^3, and may be harmful if started more than 10 years after menopause^4. <1+> In the 13-year follow-up of women in the WHI, the cumulative data in the 50–59-year-old age group showed a reduction of coronary heart disease (CHD) (HR 0.65; 95% CI 0.44–0.96). The risk of myocardial infarction was also significantly decreased (HR 0.60; 95% CI 0.39–0.91)^5. <1+> However, in this age group, the women receiving estrogen–progestogen (CE + MPA) in the WHI trial did not receive any overall CHD benefit (HR 1.27; 95% CI 0.93–1.74)^6. Women <10 years since menopause who received CE + MPA showed a non-significant reduction in CHD (HR 0.90; 95% CI 0.56–1.45), suggesting a potential attenuation of the coronary benefit with this particular regimen using a continuous progestogen^5. <1->

Meta-analyses of RCTs, including data from the WHI, have shown a significant reduction in CHD as well as mortality in women treated with estrogen under the age of 60^7. <1+++> In the WHI, the cumulative results showed a reduction in all-cause mortality in the 50–59-year-old age group with estrogen alone and estrogen–progestogen, although the point estimates just missed statistical significance (RR 0.78; 95% CI 0.59–1.03 for estrogen; RR 0.88; 95% CI 0.70–1.11 for estrogen–progestogen)^5. When mortality data for CE and CE + MPA from the two WHI trials were combined, the reduction in all-cause mortality was significantly reduced by 30%. Combining the data provided sufficient events to drive the data to significance^8. <1+> Several meta-analyses have had similar findings^9,10. In the most recent Cochrane analysis, women within 10 years of menopause had a reduction of all-cause mortality of 0.70 (95% CI 0.52–0.95) and of cardiovascular mortality of 0.52 (95% CI 0.29–0.96)^11. <1+> An observational study from Finland recently reported that estradiol products (oral and transdermal) with and without progestogen decreased coronary and all-cause mortality significantly (12–54%)^12; of note in this study, while longer duration of use decreased mortality, age of initiation did not make a difference^12. <1+++>

The three most recent prospective trials using MHT with coronary disease as the endpoint are DOPS^13, KEEPS^14 and ELITE^15.

The Danish Osteoporosis Prevention Study (DOPS) studied younger women at the onset of menopause who prospectively received standard doses of estradiol and norethisterone in an open-label fashion, or no treatment, for 10 years and had 16 years of follow-up^13. There were significant reductions in mortality and in
hospitalizations for myocardial infarction and congestive heart failure. <1+>

The Kronos Early Estrogen Prevention Study (KEEPS) did not show a difference between CEE 0.45 mg, transdermal estradiol 0.05 mg and placebo in terms of intermediate endpoints: carotid artery intima-media thickness and coronary calcium14. These young healthy women had virtually no atherosclerosis and it is possible that there was insufficient progression over 4 years to detect differences between the groups. <1+>

The Early versus Late Intervention Trial with Estradiol (ELITE)15 studied the effects of oral estradiol 1 mg and placebo in two groups of women, one <6 years from menopause and the other > 10 years from menopause, and showed a reduction in carotid artery intima-media thickness over time in the younger women, and no change in the older population, confirming that the ‘timing’ of estrogen treatment is important in influencing the progression of coronary disease15. <1+>

Initiation of MHT in elderly women (> 60 years old) or those who are more than 10 years postmenopause may be associated with increased risk for coronary events. <1+> However, the cumulative 13-year data of the WHI and the recent Cochrane analysis did not show a significant increase in CHD or mortality in the older age groups <1–>; there was an increase in venous thrombosis and stroke with initiation of oral MHT in the older age groups5–11. <1+> Some data suggest that concomitant use of statins may mitigate the risk of venous thrombosis events following initiation of MHT in women over age 6016. <2++>

Key messages

- In women <60 years old, who are recently menopausal and with no evidence of cardiovascular disease, the initiation of estrogen-alone therapy reduces CHD and all-cause mortality. [A]
- The daily continuous combined oral estrogen–progestogen data are less robust but other combined therapy regimens appear to be cardioprotective, as shown in the Danish and Finnish studies. [A]
- With cardiovascular disease being the leading cause of death in women, for women starting MHT <60 years of age and/or within 10 years of menopause, the most recent Cochrane analysis, other meta-analyses, and the WHI 13-year results all show a consistent reduction in all-cause mortality. [A]
- It is not recommended to initiate MHT beyond age 60 years solely for primary prevention of CHD. [A]

Stroke

The risk of ischemic stroke is related to age, but stroke is a rare event before age 601. Stroke incidence may be increased when MHT is initiated in women > 60 years of age, but is not associated with hemorrhagic stroke. <1+>

Initiation of MHT in women < 60 years of age and/or < 10 years since menopause has no effect on the risk of stroke according to data from the 13-year follow-up data from the WHI and the Cochrane analysis2,3. <1+> The risk of ischemic stroke with MHT may be related solely to oral therapy, with lower doses having a smaller risk and no significant risk occurring with transdermal therapy4, suggesting a primary thrombotic mechanism5. <2–>

Coagulation, venous thromboembolism disease and MHT

Venous thromboembolism events are the most prevalent adverse effect of oral estrogens in recently postmenopausal women. The MHT-related risk for serious venous thromboembolic events increases with age (although rare in low-risk women until age 60 years) and is also positively associated with obesity and thrombophilia. Epidemiological studies have not found any increased risk of VTE with use of transdermal estrogen. There is also strong evidence that the type of progestin associated with estrogen is of importance. Biological evidence supports all of these results. The use of transdermal estrogen associated with progesterone might be safer in regard to VTE, especially in women at high VTE risk.

The incidence of VTE (both deep vein thrombosis and pulmonary embolism) is estimated to be one to two cases per 1000 woman-years1–3. VTE strongly increases with age. Obesity, personal history of thrombosis (superficial or deep) and genetic thrombophilia are common VTE risk factors14.

Venous thrombosis and oral estrogen with or without progestogen

Based on the results of RCTs and observational studies, the incidence of VTE is higher during the first year of oral estrogen use, with or without progestogen5,6. The initiation of MHT in older women and, to a lesser extent, the continued use of MHT are associated with an increased risk as compared to non-users. In the WHI, in the 50–59-year-old group, the excess risk of pulmonary embolism was six additional cases per 10 000 woman-years for estrogen–progestogen therapy, and four additional cases with estrogen
alone; both are far less than the risk of VTE in normal pregnancy\(^7\). \(<1+>

Whether the type of estrogen molecule is associated with different levels of venous risk remains controversial. In a recent population-based, case–control study of oral hormone therapy users, CEE use was associated with a higher risk of incident VTE than estradiol use\(^8\). These results need to be confirmed. \(<2>\)

**Impact of progestogen with oral estrogen**

The risk of a thromboembolic event may also be affected by the type and duration of progestogen. MPA may be associated with greater risk when used in oral therapy, as is the use of continuous combined regimens compared with sequential regimens. Moreover, the CEE arm of the WHI had a non-significant hazard ratio of VTE, especially in younger women\(^6,7\). \(<1+>\)

**Venous thrombosis and transdermal estrogen with or without progestogen**

Less than ten observational studies have assessed the risk of VTE associated with transdermal estrogen therapy\(^3\). Meta-analyses of these epidemiological studies have shown that transdermal estrogen did not increase the risk of VTE. The hazard ratio for VTE among users of transdermal therapy was close to one\(^9\), \(<2++>\)

Two observational studies underline the importance of the type of progestogen associated with estradiol\(^10–12\). Thus, these studies pointed to an increased risk of VTE in women using transdermal estrogen combined with norpregnane derivatives as compared to women using progesterone. \(<2+>\)

**Venous thrombosis, route of administration and genetic markers**

The combination of thrombogenic mutations and oral estrogen, especially CEE with or without progestogen, further enhanced the risk of VTE compared with women without mutations\(^2,3\). \(<1–>\)

In only one study, no significant difference was observed in risk of VTE between women with the factor V Leiden mutation or prothrombin G20210A mutation who used transdermal estrogen and those with a mutation who did not use estrogen\(^13\). \(<2+>\)

**Venous thrombosis, route of administration and clinical risk factors**

Obesity or personal history of VTE are major venous risk factors. The combination of oral estrogen use and an increased BMI resulted in a further increase in the VTE\(^2,3\). \(<1+>\)

In one study, however, current use of transdermal estrogen did not confer an additional risk on women who were overweight or obese\(^14\). \(<2>\)

Moreover, only one retrospective cohort study has assessed the impact of MHT by route of estrogen administration on the risk of recurrent VTE\(^15\). Oral but not transdermal estrogens are associated with a higher risk of recurrent VTE among postmenopausal women. This result needs to be confirmed by larger studies. \(<2>\)

**Coagulation plausibility**

Biological evidence supports the observation of an increased VTE risk among users of oral estrogen therapy and a neutral impact among users of transdermal estrogen therapy. Orally administered estrogen (estra
diol or CEE) may exert a prothrombotic effect through the hepatic impact of these molecules\(^16–20\). The prothrombotic effect is possibly related to high concentrations of estrogen in the liver due to the ‘first-pass’ effect. Randomized trials that compared oral and transdermal estradiol therapy have demonstrated that transdermally administered estrogen has no or little effect in elevating prothrombotic factors and may have beneficial effects on proinflammatory markers. \(<1++>\)

**Recommendations and key messages**

- Oral estrogen therapy is contraindicated in women with personal history of VTE. [A]
- Transdermal estrogen therapy should be the first choice in obese women suffering from climacteric symptoms. [B]
- The risk of venous thrombosis increases with age and in the presence of other risk factors, including congenital or acquired thrombophilic disorders. ✓
- A careful assessment of personal and family history of VTE is essential before prescribing hormone therapy. ✓
- The risk of venous thromboembolic events increases with oral MHT but the absolute risk is rare below age 60 years. ✓
- Observational studies point to a lower risk with low-dose transdermal therapy associated with progesterone, underlined by a strong biological plausibility. ✓
- Some progestogens, e.g. MPA, norpregnane derivatives and continuous combined regimens,
may be associated with greater risk of VTE in oral MHT users. [C]
- The incidence of VTE is less frequent among Asian women. [C]
- Population screening for thrombophilia is not indicated prior to MHT use. [C]
- Selective screening may be indicated on the basis of personal and familial history. [D]

Central nervous system

Purpose and scope

This section of the guideline reviews evidence on effects of MHT and related compounds on cognition, mood, and other neurological disorders. MHT use during midlife is of particular interest, as MHT is most likely to be initiated and used during the menopausal transition and early postmenopause. Moreover, some health-related outcomes may differ for midlife MHT use compared to MHT use later in the postmenopause. For cognition, we sought evidence regarding cognitive change in women without cognitive impairment (cognitive aging), cognitive change in women with Alzheimer’s disease, and risks of developing Alzheimer’s disease or another form of dementia. For mood, we examined outcomes in midlife women with and without depression. For epilepsy, migraine headache, multiple sclerosis, and Parkinson’s disease, we sought evidence on associations of MHT with disease risk and symptoms.

Does MHT initiated and used during midlife affect cognitive aging?

Forgetfulness, trouble concentrating, and other cognitive symptoms are common during midlife. During the menopausal transition, many women experience transient cognitive impairment, which is usually of small magnitude. There is likely no persisting effect of the natural menopause on memory or other cognitive functions. A large, long-duration, three-arm trial of MHT in women below age 60 years showed no cognitive benefit or harm after mean treatment periods of 2.85 years (CEE 0.45 mg/day or transdermal estradiol 0.05 mg/day, with cyclical oral progesterone, versus placebo). In follow-up analyses from the WHI approximately 7 years after trial termination, there was no residual cognitive effect of CEE 0.625 mg/day, with or without continuous MPA, begun at age 50–55 years.

Surgical menopause is distinguished from natural menopause by social and demographic features. Moreover, the transition is abrupt, occurs at an earlier age, and involves the loss of androgens as well as estrogens and progesterone. Results from small, short-duration clinical trials in surgically menopausal women suggest that estrogen therapy could be of short-term cognitive benefit when initiated at the time of oophorectomy. <1-->

Does MHT initiated after midlife affect cognitive aging?

MHT has been assessed in four large, long-duration trials in healthy postmenopausal women aged 60+ years. Overall findings indicated no significant cognitive benefit or harm after mean follow-ups of 3 years (CEE 0.625 mg/day and continuous MPA, women with a uterus), 3 years (CEE 0.625 mg/day, women without a uterus), 3 years (CEE 0.625 mg/day with or without continuous MPA), or 2 years (transdermal estradiol 0.014 mg/day).

Does MHT affect cognitive symptoms of women with Alzheimer’s disease or dementia?

For Alzheimer’s disease, older women without a uterus were assessed in a large, long-duration trial (unopposed CEE 0.625 or 1.25 mg/day, or placebo). Findings were null, and results from most small, short-duration trials similarly suggest no important effect of MHT on cognitive outcomes.

Does midlife MHT affect the risk of dementia?

Older systematic reviews of case-control and cohort studies suggest risk reductions associated with MHT use of about 34–44%. Risk reductions are similar in observational studies where hormone exposure was assessed prior to dementia onset, reducing the likelihood of recall bias.

Does MHT initiated after midlife affect the risk of dementia?

Two large, long-duration ancillary studies from the WHI examined MHT (unopposed CEE 0.625 mg/day, women without a uterus; CEE 0.625 mg/day combined with MPA, women with a uterus) with outcomes of all-cause dementia. The number of events was small (108 dementia cases in the two trials combined), and Alzheimer’s disease was not examined separately. For unopposed estrogen therapy, the hazard ratio (HR) was not significantly different from 1; for combined therapy, it was increased. In an analysis that combined both...
hormone groups, the HR for MHT use was significantly elevated (HR 1.8, 95% CI 1.2–2.6)\textsuperscript{14}. <1+>

Trial participants were 65–79 years old. Dementia attributed to combined MHT was uncommon in this age group, about 2.3 cases per 1000 woman-years of use. For unopposed estrogens, the point estimate of attributable risk was less, 1.2 per 1000 woman-years of use. Extrapolating these risk estimates to healthy women aged 50–59 years – an age group not studied in these trials – implies that dementia risk attributable to MHT would be rare among younger postmenopausal women, about 0.2 additional cases per 1000 woman-years.

**Risk of Alzheimer’s disease and dementia – effect of age**

Discrepant findings on dementia risk from observational studies of midlife MHT use and the WHI clinical trials could reflect unrecognized confounding in observational studies, failure of findings in older postmenopausal women to generalize to younger postmenopausal women, or both\textsuperscript{15}. Three observational studies explored possible differences based on timing. One found reduced Alzheimer risk for MHT use among younger, but not older, postmenopausal women\textsuperscript{16}. Another described reduced dementia risk for MHT used during midlife and not during old age, contrasted with increased dementia risk for MHT used during old age but not during midlife\textsuperscript{17}. The third reported reduced Alzheimer risk for MHT initiated within 5 years of menopause but no effect on risk for MHT initiated more than 5 years after menopause\textsuperscript{18}. These observational findings support the critical window, or timing, hypothesis of MHT for Alzheimer risk\textsuperscript{15}. <2+>

**What are the cognitive effects of other estrogenic compounds?**

The SERM raloxifene is approved for the treatment of osteoporosis in postmenopausal women. In a large, long-duration trial of raloxifene in postmenopausal women with osteoporosis, raloxifene (60 and 120 mg/day) had no effect on most neuropsychological measures\textsuperscript{19}. High-dose (120 mg/day) but not standard dose (60 mg/day) raloxifene reduced risk of mild cognitive impairment (RR 0.67; 95% CI 0.46–0.98)\textsuperscript{20}. <1+> High-dose raloxifene does not significantly affect cognition in women with Alzheimer’s disease, although clinical trial results do not exclude the possibility of small cognitive effects\textsuperscript{21}. <1+>

Two large, long-duration trials examined cognitive effects of soy isoflavone supplements in healthy postmenopausal women. A study of older postmenopausal women identified no significant effect on neuropsychological performance after 12 months\textsuperscript{22}. Another study, which included both younger and older postmenopausal women, found no effect on individual neuropsychological measures or a global composite derived from all measures after 2.5 years; effects were similar in younger and older women\textsuperscript{23}. Visual memory improved significantly among women assigned to the isoflavone group compared to the placebo group, but performances on other cognitive factors did not differ\textsuperscript{23}. <1+>

**What are the effects of MHT on midlife depressive symptoms and depression?**

The incidence of major depression is probably similar in old age compared to younger age groups\textsuperscript{24}, but depression and depressive symptoms are more common during the menopausal transition and early postmenopause than shortly before the menopause\textsuperscript{1}. <2+ to 2–>

Findings are inconsistent as to whether MHT improves or has no effect on depressive symptoms in younger postmenopausal women without depression. A large 4-year study reported that CEE (0.45 mg/day, with cyclic progesterone) but not transdermal estradiol (0.05 mg/day, with cyclic progesterone) improved depressive symptoms compared to placebo\textsuperscript{3}. A large 4-month trial found no effect on affect for CEE (0.625 mg/day, with continuous MPA)\textsuperscript{25}. <1+>

Two small, short-duration clinical trials assessed MHT in women with depression or depressive symptoms during the menopausal transition. After 3 weeks, depression scores improved significantly in depressed women treated with transdermal estradiol (0.05 mg/day) compared to placebo\textsuperscript{26}. After 12 weeks, depressive disorders were significantly more likely to remit with transdermal estradiol (0.1 mg/day) compared to placebo\textsuperscript{27}. <1–>

**What are the effects of MHT on other neurological disorders?**

Hormone exposures are of potential relevance to a number of neurological disorders. Estrogens have been linked to migraine headache\textsuperscript{28}, and headache prevalence is lower after menopause than before\textsuperscript{29}. There are no clinical trial data on MHT and headache symptoms or frequency. Multiple sclerosis symptoms are widely believed to be influenced by hormonal status, but relevant clinical trials are not yet reported\textsuperscript{30}. For Parkinson’s disease, observational studies suggest no consistent association between MHT use and Parkinson risk\textsuperscript{31}. A small, under-powered, 8-week pilot trial (CEE...
0.625 mg/day) in postmenopausal women with advanced Parkinson’s disease showed no significant effect of MHT on study outcomes. For some women of reproductive age with epilepsy, seizure frequency varies in association with the menstrual cycle. A small, 3-month clinical trial in midlife postmenopausal women with epilepsy reported that CEE (0.625 mg/day or 1.25 mg/day, combined with MPA) led to a dose-related increase in seizure frequency. <1– to 2–>

**Key messages**

**Cognitive aging**
- MHT should not be used to enhance cognitive function. [A]
- Healthy women considering MHT for approved indications need not be overly concerned that MHT will adversely affect cognitive function. [A]
- Estrogen therapy may be of short-term cognitive benefit to surgically menopausal women when initiated at the time of oophorectomy. [B]
- Phytoestrogen (soy isoflavone) supplements used by healthy postmenopausal women in a daily dose comparable to that consumed in traditional Asian diets have no overall effect on cognition. [A]

**Alzheimer’s disease and dementia**
- For women with Alzheimer’s disease, MHT initiated after the onset of dementia symptoms does not benefit cognitive function or slow disease progression. [A]
- MHT initiated and used after midlife increases risk of dementia. [A]
- MHT initiated during midlife is associated with reduced risk of Alzheimer’s disease and dementia. [B]
- Extrapolated from risks in older postmenopausal women, estimates in women younger than 60 years imply that dementia risk attributable to MHT would be rare in this age range. [D]

**Depressive symptoms and depression**
- Findings are inconsistent as to whether MHT improves or has no effect on depressive symptoms in younger postmenopausal women without depression. [A]
- For depression or depressive disorders that occur during the menopausal transition, short-term estrogen therapy may improve affective symptoms or increase the likelihood of remission. [B]

**Other neurological disorders**
- MHT may increase seizure frequency in women with epilepsy. [B]
- MHT is not associated with Parkinson’s disease risk. [B]
- Effects of MHT on symptoms of migraine headache, multiple sclerosis, and Parkinson’s disease are largely unknown. [B]

**Breast cancer**
The incidence of breast cancer varies in different countries. Therefore, currently available data may not be applicable everywhere. The degree of association between breast cancer and MHT remains controversial. Most long-term studies reflect the use of one specific combination of oral estrogen and progestogen and suggest a possible increased risk with increasing duration. The WHI estrogen + progestogen trial and several large observational studies reported an increased risk after at least 5 years of use, suggesting a possible promoter effect on existing tumors. Only the unadjusted relative risk was significant and, when adjusted on risk factors, the significance was no longer reached. Combined MHT can increase breast density, which complicates screening and increases mammography frequency. <1+>

The possible increased risk of breast cancer associated with MHT is small and estimated at less than 0.1% per annum, or an incidence of <1.0 per 1000 women per year of use. It is similar or lower than the increased risks associated with common lifestyle factors such as reduced physical activity, obesity and alcohol consumption. Data from the WHI study demonstrated no increased risk in first-time users of MHT during the 5–7 years since initiation of treatment. The WHI study also demonstrated that 7.1 years of treatment with unopposed CEE decreased the risk of breast cancer diagnosis and mortality in hysterectomized women. However, the majority of subjects in the WHI study were overweight or obese, which may have affected their basal breast cancer risk. The estrogens used were conjugated estrogens and not estradiol. This cannot reliably be extrapolated to younger and less obese women and to estradiol.

There is no randomized head-to-head study between estrogen alone and combined MHT but several observational studies including the Nurses’ Health Study suggest that long-term administration of unopposed estrogens alone can be associated with a small increase in the relative risk of breast cancer in leaner, younger...
women, but that potential risk is lower than that associated with combined treatment\textsuperscript{5,6,9}.\textsuperscript{2+}

Tibolone does not appear to be associated with an adverse effect on mammographic density\textsuperscript{10}. The risk of breast cancer with tibolone is not fully evaluated in normal women but tibolone increases the rate of recurrence in breast cancer survivors\textsuperscript{11}.\textsuperscript{1+}

Three studies suggest that micronized progesterone or dydrogesterone could be associated with a lower risk than synthetic progestogen. A large European observational study suggested that micronized progesterone or dydrogesterone used in association with oral or percutaneous estradiol may be associated with a better risk profile for breast cancer than synthetic progestogens\textsuperscript{6}.\textsuperscript{2+} A case–control study from France also showed a lower level of risk with progesterone than synthetic progestogens\textsuperscript{12}.\textsuperscript{2→} A registry study from Finland reported no increase in risk with dydrogesterone after at least 5 years of use compared to synthetic progestogens, which were associated with a small increase in risk\textsuperscript{13}.\textsuperscript{2+} Currently available data imply no difference in risk between oral and transdermal routes of estradiol administration\textsuperscript{4}.\textsuperscript{2+} However, there are not enough data from adequately powered clinical studies to fully evaluate possible differences in the incidence of breast cancer using different types, doses and routes of estrogen, type of progestogens and androgen administration.

**Key messages**

- The risk of breast cancer in women over 50 years associated with MHT is a complex issue.
- The risk associated with unopposed estrogen therapy is dependent on dose and duration of treatment\textsuperscript{5}.\textsuperscript{2+} The addition of a progestogen, in either continuous combined or cyclical fashion, has been shown to reduce the risk of endometrial neoplasia associated with estrogen therapy\textsuperscript{6}.\textsuperscript{1+} Inhibiting progression of estrogen-induced proliferation to hyperplasia will depend on the dose and duration of progestogen used. Unopposed estrogen for 1 year yielded a 20% incidence of hyperplasia\textsuperscript{7}.\textsuperscript{1+} Cyclic progestogen given for more than 10 days monthly reduces this rate to that seen with placebo\textsuperscript{6}, whereas continuous combined MHT is rarely associated with endometrial hyperplasia.\textsuperscript{1+} In the WHI, which employed continuous combined MHT, there was a statistically non-significant 19% decline in endometrial hyperplasia compared to placebo\textsuperscript{6}.\textsuperscript{1+}

- Annual mammograms should be proposed in case of high breast density in women using MHT. [D]

**Endometrial safety and bleeding**

Virtually all health-care providers are aware of the fact that postmenopausal bleeding is ‘endometrial cancer’ until proven otherwise, although only 1–14% of such patients will actually prove to have endometrial cancer\textsuperscript{1}.\textsuperscript{1+} Endometrial evaluation in any postmenopausal patient with bleeding, whether on no medication, MHT, or a SERM, requires evaluation. The evaluation of bleeding has undergone a transformation in the past few years with the recognition that endometrial pathologies are not always global and, thus, blind endometrial biopsies, when negative, are not nearly as significant or reliable as when positive\textsuperscript{2}. Blind sampling is still an appropriate first step in evaluation. However, if not positive for cancer or atypical complex hyperplasia, techniques like saline infusion sonohysterography or hysteroscopy, preferably in an office setting, are necessary to triage global versus focal processes\textsuperscript{2}. Blind endometrial sampling has been shown to be very effective if a cancer occupies more than 50% of the surface area of the endometrium\textsuperscript{3}.\textsuperscript{2+}

In terms of MHT, the association of unopposed estrogen therapy with endometrial hyperplasia/neoplasia is well known\textsuperscript{4}.\textsuperscript{1+} The risk associated with unopposed estrogen therapy is dependent on dose and duration of treatment\textsuperscript{5}.\textsuperscript{2+} The addition of a progestogen, in either continuous combined or cyclical fashion, has been shown to reduce the risk of endometrial neoplasia associated with estrogen therapy\textsuperscript{6}.\textsuperscript{1+} Inhibiting progression of estrogen-induced proliferation to hyperplasia will depend on the dose and duration of progestogen used. Unopposed estrogen for 1 year yielded a 20% incidence of hyperplasia\textsuperscript{7}.\textsuperscript{1+} Cyclic progestogen given for more than 10 days monthly reduces this rate to that seen with placebo\textsuperscript{6}, whereas continuous combined MHT is rarely associated with endometrial hyperplasia.\textsuperscript{1+} In the WHI, which employed continuous combined MHT, there was a statistically non-significant 19% decline in endometrial hyperplasia compared to placebo\textsuperscript{6}.\textsuperscript{1+}

Adequate endometrial protection was demonstrated in MHT users with sequential and continuous micronized progesterone in the PEPI trial\textsuperscript{7}.\textsuperscript{1+} However, in the EPIC prospective cohort study, more endometrial cancers occurred in sequential combined estradiol/micronized progesterone MHT users: HR 2.42 (95% CI
A possible explanation is that there was reduced compliance in estradiol/micronized progesterone users because there were two separate components to their MHT.

The levonorgestrel-releasing intrauterine system (IUS) has been reported to be more effective than sequential MPA but comparable to other systemic progestogen regimens for endometrial protection in perimenopausal and postmenopausal women taking estrogen therapy10. <1+>

More recently, a regimen combining the SERM, bazedoxifene, with CEE has been introduced as a progestogen-free alternative for MHT in women with a uterus11. <1+> Attempts to combine other SERMs with estrogens resulted in an unacceptably high incidence of endometrial hyperplasia12. <1+>

Because the addition of progestogen, especially sequentially, may produce unwanted side-effects, there have been attempts to prescribe ‘long-cycle’ progestogen supplementation with mixed results, but these used different regimens. In one study that compared long-cycle (12 weeks) with traditional (4 weeks) supplementation, there was an increase in neoplasia13. <2+> Another attempt, simply comparing patient outcomes to ‘acceptable rates of hyperplasia’ as defined by regulatory agencies, found long-cycle use (12 weeks) to be appropriate14. <2–>

Tibolone is also used extensively as a form of MHT. It is not, however, available world-wide. A large epidemiological study showed a statistically significant, almost three-fold increase in endometrial cancer compared to never-users of MHT over a mean follow-up of 9 years15. <2+> However, other studies have found that tibolone does not induce endometrial hyperplasia or carcinoma in postmenopausal women and was associated with a better vaginal bleeding profile than CEE + MPA in a continuous combined fashion16. <1+>

The use of SERMs, although not strictly a form of MHT, is increasing. Thus, they deserve mention here. Tamoxifen, the first real SERM, has a small but definite association with endometrial neoplasia17. <1+> As a result, virtually every other SERM has undergone clinical programs to evaluate uterine safety.Raloxifene and bazedoxifene, used in low to medium dose, have a similar effect on the postmenopausal endometrium as placebo18,19. <1+> In higher doses (30–40 mg daily), bazedoxifene appears to reduce endometrial thickness. Ospemifene, approved for oral treatment of vulvovaginal atrophy/genitourinary syndrome of menopause, has demonstrated endometrial safety20,21. <1+> Lasofoxifene, approved in the European Union but not the United States and never commercially developed, had proven endometrial safety through a 5-year randomized, placebo-controlled osteoporosis study22. <1+>

**Key messages**

- Postmenopausal bleeding is ‘endometrial cancer until proven otherwise’, although only 1–14% of such patients will actually have cancer. [A]
- Blind endometrial sampling is appropriate for initial evaluation but is only reliable when endometrial cancer exceeds more than 50% of the endometrial surface area. [B]
- Adequate doses of micronized progesterone appear to be 200 mg per day for 10–14 days in sequential therapy and 100 mg per day for continuous combined therapy where the estradiol dose is 2 mg/50 μg or less. [B]
- Higher doses of progesterone may be required for endometrial protection when higher doses of estradiol are used, or in women with high BMI. [B]
- Unopposed estrogen therapy is associated with a duration and dose-related increase in risk of endometrial hyperplasia and cancer. [A]
- Endometrial protection requires an adequate dose and duration of progestogen. [A]

**Ovarian cancer**

The IMS recommendations of 2013 stated that ‘Long-term, estrogen-only therapy may be associated with a small attributable risk of ovarian cancer of 0.7 per 1000 women per 5 years of use, whilst either a smaller, or no, increased risk is seen with combined E + P therapy’1.

A meta-analysis of 52 studies, principally focused on 17 follow-up studies, has since been published, in which it has been claimed that MHT (both estrogen-only and E + P) increases the risk of ovarian cancer by some 1.2–1.4-fold, both overall, and even when currently used, or last used less than 5 years previously, and even when such use lasted less than 5 years. <2++> The increased risks were confined to serous and endometrioid tumors. The attributable risk for 5 years of use at age 50 years was given as one extra case per 1000 users, and one extra death per 1700 users.

It has further been claimed that the increased risk ‘may well be largely or wholly causal’, and that claim has attracted considerable publicity. However, the validity of the evidence has been challenged, for the following reasons:

- The likelihood that symptoms of as yet undiagnosed ovarian cancer (e.g. dyspareunia, urinary symptoms) were attributed to the menopause, and resulted in the use of MHT;
Lung cancer incidence ranks second in the list of female cancers, but it has surpassed breast cancer as the leading cause of cancer death among females in more developed countries\(^1,2\). Advanced age and smoking are the main risk factors. <2++> A large, prospective, observational study from China suggested that lung cancer incidence might be higher in women who had gone through menopause at baseline compared to women of the same age who were still menstruating\(^3\). <2+> A case–control study from Italy found that age at menopause above 51 years was associated with risk reduction as well. <2--> The risk did not substantially change among women with longer duration of MHT. A meta-analysis of 18 various types of studies (RCTs, case–control, cohort, cancer registry) showed an overall benefit for ever use of MHT (RR 0.80, 95% CI 0.72–0.89)\(^5\). <2++] However, the reduction in risk was seen in estrogen-only users, whereas there was no significant effect associated with combined E + P use. The authors noted that significances were found in analyses only when smoking and non-smoking women, various hormone regimens, or histological subtypes, respectively, were pooled. A large-scale, observational, prospective study from California reached a conclusion that there was no association between intake of MHT and lung cancer risk after adjustments for smoking, histology of the tumor, type of menopause and of the hormone preparation\(^6\). <2+> The WHI clinical trials actually had the same conclusions\(^7,8\): HR 1.17, 95% CI 0.81–1.69 in the estrogen-alone arm; HR 1.23, 95% CI 0.92–1.63 in the E + P arm, but more women died from lung cancer in the combined MHT group than in the placebo group (HR 1.71, 95% CI 1.16–2.52). <1+> Further analyses from the WHI study, whether an overview of findings from the two WHI clinical trials with extended post-intervention follow-up\(^9\), or a joint analysis of the WHI observational study data and the clinical trial data\(^10\) reached similar conclusions of no overall effect. Two subgroups in the latter study did show significant associations: for all lung cancers, women with previous use of E + P of <5 years were at reduced risk (HR 0.84; 95% CI 0.72–0.98), and a similar risk reduction for non-small cell lung cancer was recorded for 5 to <10 years of any previous hormone use (HR 0.84; 95% CI 0.71–0.99). Later age at menopause was associated with risk reduction as well. <1+> To summarize, data on MHT and lung cancer are inconsistent and do not point at a clear association of MHT in the pathogenesis or outcome of pulmonary malignancies.

**Key messages**
- Neither of the two WHI clinical trials (estrogen-alone or E + P) demonstrated a significant increase in lung cancer incidence among hormone users compared to placebo. [A]
- In the WHI E + P clinical trial, the risk of death from lung cancer was higher. However, there was no effect on mortality in the 50–59-year-old women. [A]
- Combining data from the WHI clinical and observational studies allowed identification of subgroups in which MHT proved protective: for all lung cancers – previous use of E + P for less than 5 years; for non-small cell lung cancer – previous use of any MHT for 5–10 years. [B]
Colorectal cancer

Colorectal cancer is one of the leading types of cancer in women. Its incidence varies in different world regions, with an age-adjusted range between 3 and 33 per 100 000 women. Incidence strongly increases with age; median age at diagnosis is about 70 years in developed countries. Many risk factors may have an impact (family history, smoking, obesity, diet and lifestyle, etc.), but MHT is mentioned in this context as well. The Nurses’ Health Study, a very large prospective, observational study from the USA, found that the RR of colorectal cancer in current hormone users was 0.65 (95% CI 0.50–0.83). In a meta-analysis of 18 epidemiologic studies of MHT and colorectal cancer, the same group reported on a 20% reduction (RR 0.80, 95% CI 0.74–0.86) in risk of colon cancer and a 19% decrease (RR 0.81, 95% CI 0.72–0.92) in the risk of rectal cancer for postmenopausal women who had ever taken hormone therapy compared with women who never used hormones. Both the WHI clinical trials (randomized, placebo-controlled) provided data on colon cancer and MHT which were not in line with the previous observational studies. On the one hand, the E + P study in women with a uterus did show a benefit, with RR = 0.63 (95% CI 0.43–0.92) for the hormone users, but, on the other hand, there was no significant effect of estrogen-alone on the incidence of colorectal cancer in hysterectomized women (RR 1.08; 95% CI 0.75–1.55). The reduced risk in the E + P study was predominantly for local disease and, where spread had occurred, there was more node involvement and a more advanced stage at diagnosis amongst users of MHT. Further data from the WHI projects were published in later years, either combining the results from the clinical and the observational trials, or combining the clinical trials with some additional years of follow-up post-stopping of therapy; they were summarized as yielding an insignificant effect or having no important clinical effect. It should be noted that all US studies actually used one specific hormonal medication, namely CEE and MPA. In a large, observational study from France, where most women take estradiol and non-MPA progestogens, ever-use of MHT (all types and routes) was not associated with risk for adenoma or cancer, but ever-use of estrogen-alone was associated with increased risk for adenoma (HR 1.22, 95% CI 1.05–1.41), whereas a decreased risk of cancer (HR 0.72; 95% CI 0.56–0.94) was reported. Tibolone is another type of non-estrogenic MHT, which is often prescribed in Europe. A randomized, placebo-controlled study on osteoporotic women gave encouraging results concerning the risk of colon cancer, with a relative hazard 0.31 (95% CI 0.10–0.96). In conclusion, on the whole there seems to be a beneficial impact of MHT on colon cancer risk, but data are inconsistent with regard to estrogen-alone treatment. MHT should not be used solely for the prevention of colorectal cancer.

Cervical cancer

Cervical cancer is the fourth most common cancer world-wide for females, and the seventh most common cancer overall, with more than 527 000 new cases diagnosed in 2012 (8% of female cases and 4% of the total). Incidence rates of cervical cancer are highest in Eastern Africa and lowest in Western Asia, Australia, New Zealand and North America. The peak age for developing cervical cancer is 30–35 years in western countries and declines steadily after this until a second peak in incidence in very old age. National screening programs in many developed countries have led to a
significant decrease in incidence rates and, in particular, the incidence in women aged over 45 years has declined significantly since the mid-1970s.

The uterine cervix is a part of the female reproductive tract that is highly responsive to estrogen. However, the role of estrogen in cervical cancer, which is strongly associated with HPV infections, until now is poorly understood.

Investigating the correlation between MHT and cervical cancer risk has been hampered to a much greater extent than the assessment of hormonal contraceptives by two main problems: first, the predominant use of MHT is in rich countries where cervical cancer risk has been greatly reduced by cytological screening, and, second, there is the additional tendency of MHT users to be screened more intensively than non-users. Long-term cohort studies have shown no increased risk of cervical cancer with MHT use. The only relatively unbiased data on MHT and cervical cancer and precancerous lesions derive, therefore, from the two randomized, placebo-controlled studies, the WHI and the Heart and Estrogen/progestin Replacement Study (HERS).

In the WHI (combined arm) with cytological findings assessed during a 6-year follow-up period, the annual incidence rate of any cytological abnormality in the MHT group was significantly higher than in the placebo group (HR 1.4; 95% CI 1.2–1.6), but no difference was found in incidence rates of high-grade squamous intraepithelial lesions, which would be comparable to cervical intraepithelial neoplasia 2/3 and cervical cancer. A non-significantly higher incidence of cytological abnormalities (HR 1.4; 95% CI 0.9–2.0) was reported among women in the MHT group in HERS but, like the WHI, the risk of cervical cancer was not increased.

Any association between MHT use and adenocarcinoma of the cervix is unclear. Recently, a retrospective Finnish registry study investigating postmenopausal women (n = 243,857) using 5 years MHT found an increased risk of adenocarcinomas (SIR (standardized incidence ratio) 1.83; 95% CI 1.24–2.59), whereas the risk for squamous cell carcinoma decreased (SIR 0.34; 95% CI 0.16–0.65). Further studies are needed in this area of research.

Key messages

- In the WHI randomized, controlled trials and in HERS, there was no increase in risk of cervical cancer with MHT use. [A]
- Long-term cohort studies have shown no increased risk of cervical cancer with MHT use. [B]

Upper gastrointestinal tract cancers

Hepatocellular cancer

Hepatocellular carcinoma (HCC) is an uncommon malignancy and few studies have looked into any associations with MHT. Examination of data from a framework of case–control studies conducted in Italy revealed an OR of 0.2 (95% CI 0.1–0.8) for ever-users (n = 3) compared with never-users (hospital-based controls, n = 102). However, a recent study with pooled data from 11 cohorts in the US assessing 800,000 women found no effect of MHT as a whole or when analyzed by age at natural menopause, past or current use, type of hormone and duration of exposure. The investigators did discover, however, that bilateral oophorectomy was associated with a significantly increased risk of HCC (HR 2.67; 95% CI 1.22–5.85). They suggested that the previous positive associations would disappear if proper adjustments for oophorectomy had been done.

Key messages

- There is no clear association between MHT use and HCC. [C]
- Bilateral oophorectomy may be associated with an increased risk of HCC. [C]

Gastric, esophageal and gallbladder cancers

In an observational, prospective study from Shanghai, China, only 2.1% of person-years were related to postmenopausal women who were exposed to MHT, and the incidence of gastric cancer among this subgroup was similar to that in never-users. Interestingly, the study also found that increasing time since menopause and shorter years of fertility were associated with an increased risk of gastric cancer. This would be in line with previous studies, which demonstrated a protective effect of MHT in populations with higher rates of hormone use. A nested case–control study from the UK showed that current use of MHT was associated with a reduced risk of gastric cancer (OR 0.56; 95% CI 0.33–0.96) as well as past use (OR 0.25; 95% CI 0.09–0.70). In fact, a meta-analysis of seven observational studies (cohort and case–control) pointed to the same association: comparing ever-users with never-users of MHT demonstrated a significant reduction in gastric cancer risk (RR 0.77; 95% CI 0.64–0.92). Although gender differences in susceptibility for esophageal cancer suggest a role for estrogen, there have been relatively few studies that examine possible links with MHT. Lindblad and colleagues’ database
included 299 patients with esophageal cancer, in whom no association between the tumor risk and MHT was detected (OR 1.17; 95% CI 0.41–3.32)⁴. <2—> Yet a meta-analysis of eight cohort studies of various types showed a beneficial effect with a 28% reduction in pooled risk in the hormone users (RR 0.72; 95% CI 0.60–0.86)⁴. <2++>

While it is well established that the rate of gallbladder disease may be even 50% higher among women on oral MHT, reports on an association with gallbladder cancer are lacking. A single study from Italy pointed to increased risk for those who had ever used MHT (OR 3.2; 95% CI 1.1–9.3) and the ratio tended to rise with longer duration⁷. <2—>

**Key messages**

- There are few good studies examining links between upper gastrointestinal tract cancers, menopause and MHT use.
- MHT use may be associated with a reduced risk of gastric cancer. [C]

**General and sexual quality of life in the menopause**

Healthy aging is highly relevant to general quality of life and sexual well-being and sexuality is still important to many elderly women across the menopause and beyond¹. Menopausal symptoms are strongly related to quality of life when using validated and appropriate condition-specific instruments². <1+> Both age and declining levels of sex hormones have detrimental effects on sexual functioning, with a significant increase in vaginal dryness/dyspareunia and a significant decrease in desire and sexual responsiveness³–⁶. <2+++>

Surgical menopause is more likely to be associated with sexual dysfunction, especially hypoactive sexual desire disorder, due to the more profound endocrine deprivation⁷. <2+++> Psychological and socio-relational factors are very important, influencing the clinical relevance of sexual symptoms and the level of distress in postmenopausal women. <2+++> Special attention should be paid to women with natural menopause at a younger age, because the burden of premature menopause encompasses several biopsychosocial aspects influencing quality of life and sexual well-being, including the grief of infertility in some cases⁸. <2+> Iatrogenic menopause in breast cancer survivors and in women with other malignancies is highly disruptive in the context of quality of life and sexual well-being, an issue that should be further investigated in light of the emerging reality of cancer survivors⁹. <2+>

It is mandatory to include appropriate questions to investigate sexual well-being, because women may not be willing to initiate a conversation on sexual interest, behavior and activity themselves, but they usually appreciate being questioned by doctors. Validated tools (self-administered questionnaires/daily event logs/semi-structured interviews) may be used properly to diagnose female sexual dysfunction (FSD) and to gain information on sexual constructs and relationships, taking into account the biopsychosocial model¹⁰. <2++>

Determination of circulating sex steroids is not routinely helpful and a diagnosis of androgen deficiency in healthy women should not be primarily based on measurements of androgens because their correlation with specific signs and symptoms is currently inconsistent¹¹. <1+>

The pivotal role of vulvovaginal atrophy (VVA) (referred to as genitourinary syndrome of menopause by NAMS/International Society for the Study of Women's Sexual Health, ISSWHS) should be always considered because the two most common symptoms, vaginal dryness and dyspareunia, may induce significant changes in other domains of sexual response (desire, arousal, orgasm satisfaction), as well as pelvic floor dysfunction¹²–¹₄. <2+++>

The multidimensional nature of women’s sexuality has limited the possibility to establish a clear effect of MHT on FSD. However, MHT with estrogens alone or in combination with progestogens is associated with a small to moderate improvement in sexual function, particularly in pain, when used in women with menopausal symptoms or in early postmenopause (within 5 years of amenorrhea)¹⁵–¹⁹. <1+> Tibolone, a synthetic steroid classified as a selective tissue estrogenic activity regulator, is of value in treating postmenopausal women with FSD²⁰. <1+> Hormonal and non-hormonal treatments and/or psychosexual strategies should be individualized and tailored according to a woman’s history and current needs, taking into account also the partner’s availability, general and sexual health of the partner and quality of the intimate relationship¹⁵. <2+++>

**Key messages**

- Consider age, type and time since menopause, vasomotor and mood symptoms, general health, including medications for chronic conditions, as well as intrapersonal and interpersonal factors when addressing the issue of quality of life and sexual well-being. [A]
• Do not believe that sex is not important for elderly women and try always to ‘break the ice’ in clinical practice with very simple open questions to facilitate the dialogue on sexual health. [B]
• Diagnose and routinely treat signs and symptoms of GSM/VVA to avoid the vicious circle between sexual pain and other FSD. [B]
• Always take into account the biopsychosocial model when sexual symptoms at menopause are clinically relevant in order to establish the best treatment plan. [C]

Androgen therapy for perimenopausal and postmenopausal women

Cause of female androgen insufficiency

In women, levels of testosterone and the pre-androgens, androstenedione, dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS) peak in the third to fourth decade of life and then decline with age, with the greatest decline observed in the years approaching menopause. <2+> Pathological causes of low testosterone in women include primary ovarian insufficiency, bilateral oophorectomy at any age, hypopituitarism, adrenal insufficiency and iatrogenic ovarian suppression.

Research into the role of testosterone in women has been hampered by imprecision of measurement of testosterone at the low physiological levels found in women. The use of liquid chromatography and tandem mass spectrometry has enabled the measurement of testosterone at low levels, but the issue of inter-assay variability persists even with this methodology. Other factors limiting the interpretation of testosterone levels in women include the synthesis of testosterone in peripheral target tissues so that serum levels may not accurately reflect tissue androgen exposure and that individual variations in androgen receptor sensitivity will modulate the effects of testosterone exposure.

Testosterone and female sexual function

Two recent, large, independent studies have shown strong correlations between levels of total and free testosterone, androstenedione and DHEAS and sexual desire in women aged 19–65 years, and between testosterone and masturbation frequency, sexual desire and arousal in women aged 42–52 years at recruitment to a 10-year follow-up study. These studies provide the most robust data for the relationships between androgens and female sexual function. <2+>

Testosterone therapy for the treatment of female sexual dysfunction

The primary indication for testosterone is for the treatment of diminished sexual desire that causes the affected woman to experience significant distress (previously defined as hypoactive sexual desire disorder or HSDD). Before testosterone therapy is considered, other causes of impaired sexual desire and/or arousal must be addressed. These include dyspareunia, depression, medication side-effects, relationship issues and other health problems affecting the woman or her partner.

Large, placebo-controlled RCTs have consistently show benefits of continuous testosterone therapy for women diagnosed with HSDD, with statistically significant improvements in sexual satisfaction, desire, arousal, pleasure and orgasm. <1+> These effects have been seen for naturally and surgically menopausal women, with and without concurrent MHT, and premenopausal women in their late reproductive years. Testosterone is also effective for the management of antidepressant-associated desire-arousal disorder. Most recently, HSDD and sexual arousal disorder have been re-classified as single entity: sexual interest-arousal disorder. As arousal and desire are intrinsically linked, and as testosterone therapy improves both desire and arousal, women classified in this way should be managed as women previously diagnosed as having HSDD.

Androgenic side-effects of testosterone therapy are dose-related and avoidable with the use of formulations and doses appropriate for women. There is no evidence from large, placebo-controlled RCTs that transdermal testosterone in appropriate doses results in adverse cardiovascular or metabolic effects or effects on the endometrium. Available data do not indicate an increase in risk of breast cancer with transdermal testosterone; no large study with this outcome has yet been published.

Intravaginal testosterone for treatment of vulvovaginal atrophy

Preliminary studies indicate intravaginal testosterone could provide an alternative for the treatment of VVA. <1—> Androgen receptors, aromatase (which converts testosterone to estradiol) and 5α-reductase isotypes 1 and 2 (convert testosterone to dihydrotestosterone, DHT) are present throughout the urogenital tract. Intravaginal testosterone administered alone or with vaginal estrogen has been shown to improve dyspareunia, sexual desire, lubrication and satisfaction compared with placebo. Beneficial effects have been seen with administration three times/week. These studies are
promising; larger studies are required before intravaginal testosterone can be recommended in clinical practice.

**Testosterone for the treatment of other aspects of women’s health**

Testosterone therapy has been shown to have favorable effects on bone health, with observational studies suggesting that higher testosterone levels are associated with reduced fracture risk. Fracture data from RCTs are lacking. Testosterone is not indicated for the prevention or treatment of osteoporosis. <2++>

Most observational studies show that low blood levels of total, free or bioavailable testosterone (free and albumin-bound testosterone) and low levels of sex hormone binding globulin (SHBG) are associated with a greater likelihood of atherosclerotic carotid disease, cardiovascular events and total mortality17–19. Testosterone has been shown to be a vasodilator in postmenopausal women20,21 and one small RCT of testosterone therapy in women with congestive cardiac failure demonstrated favorable cardiovascular effects22. Testosterone therapy should not be used to prevent or treat cardiovascular disease in women. <2+>

RCTs indicate a favorable, but small effect of transdermal testosterone on cognitive performance in postmenopausal women7,23,24. Although these data justify further research in this field, they do not support the use of testosterone for the prevention of cognitive decline. <1→>

**The systemic use of DHEA therapy for women**

RCTs have not shown benefits of systemic DHEA therapy over that of placebo in terms of improved sexual function, well-being or metabolic health in postmenopausal women12,25. Oral DHEA has been shown to have marginal beneficial effects on health-related quality of life and depression in women with adrenal insufficiency, but not on sexual function26. <1+>

**Intravaginal DHEA for treatment of vulvovaginal atrophy**

Daily intravaginal application of DHEA has shown favorable effects for dyspareunia and symptomatic VVA27, but these effects are not sustained when DHEA is administered twice a week28. <1→>

**Key messages**

- Androgen levels decline with age in women with no significant change associated with natural menopause. [A]

- There is strong evidence that androgens influence female sexual function and that testosterone therapy may be useful for women who have experienced loss of sexual desire and/or arousal. [A]

- Before testosterone therapy can be considered, women should be fully assessed for other treatable causes of their sexual dysfunction, and these should be addressed. [A]

- Testosterone therapy should be considered as a clinical trial, which should not be continued if a woman has not experienced a significant benefit by 6 months. [A]

**Complementary therapies, non-pharmacological and lifestyle interventions**

High-quality data from studies of non-pharmacological and lifestyle interventions for vasomotor symptoms have been limited.

The role of complementary therapies in the management of the menopause, both for symptomatic relief and avoidance of long-term complications, remains controversial. Studies and meta-analyses have not consistently supported the efficacy of complementary or over-the-counter therapies in reducing severity or frequency of hot flushes or night sweats1. <1+> Isoflavone preparations derived from soy and red clover and traditional Chinese medicines have been shown variable efficacy compared to placebo in small randomized trials and small meta-analyses1–3. <1→> Therapies such as Black cohosh and St John’s Wort have been associated with adverse effects and interactions with medications and should therefore be used with caution and appropriate medical advice4,5. <1+> Further data from larger randomized trials are required to confirm the efficacy and safety of complementary therapies.

Meditation, relaxation, controlled breathing, cognitive behavioral therapy and mindfulness training show promise in managing hot flushes, but adequately powered randomized trials are still needed6,7. <1+> Randomized trials of acupuncture have not consistently shown a beneficial effect in reducing vasomotor symptoms, although recent meta-analyses suggest a small benefit8–10. <1→> Hypnosis has been shown to reduce the frequency of vasomotor symptoms and improve sleep quality11. <1→> Although exercise has beneficial effects on mood, cardiovascular and bone health, the evidence would suggest it has little role in managing vasomotor instability12. In fact for some women it may aggravate symptom severity. <1+> Stellate ganglion blockade has been shown to reduce vasomotor symptoms by 50% over a period of several months. It appears to be a safe and well-tolerated technique13. <1+>
Key messages

- Women should be counselled that complementary therapies have limited evidence for efficacy and safety and are not regulated by the medicines agencies. [B]
- Paced respiration, cognitive behavioral therapy, mindfulness training, acupuncture, hypnosis and stellate ganglion blockade may be useful techniques to consider when treating vasomotor symptoms. [A]  

Bioidentical hormone therapy

The term ‘bioidentical’ means having the same molecular structure as a substance produced in the body1. Hence, estradiol and progesterone, as used in products manufactured by pharma companies and subjected to rigorous scrutiny by regulatory authorities, are bioidentical forms of MHT.

Bioidentical hormone therapy (BHT) is a poorly defined term commonly used as a marketing tool to describe compounded hormone preparations which contain mixtures of various hormones, including estradiol, estrone, estriol, progesterone, testosterone and DHEA, usually prepared by compounding pharmacies, but which are not subjected to the same rigorous manufacturing standards, quality control and regulatory oversight as pharmaceutical-grade registered products1,2. <2+>

Bioidentical hormones are not ‘natural’. They are synthesized in laboratories from plant-based precursors in the same way that regulated hormone products are prepared. <2+> Advertising and promotional claims made for the safety and efficacy of compounded BHT are not validated by medical evidence. <2+>

Proponents of BHT often claim, erroneously, that their preparations are made to meet individual needs of women, based on blood or salivary hormone levels. This concept is scientifically flawed, as the ratios of estrone and estriol to the parent estradiol in the body remain relatively constant, depending on the enzyme activity within cells, and it is futile for doctors to write prescriptions for all three hormones in an attempt to do what the body does naturally1.

Endometrial cancer has been associated with estrogen-containing BHT. The progesterone used in these preparations may be insufficient to inhibit estrogen-induced endometrial stimulation. <3>

Hormonal assays of saliva are sometimes claimed to be a means of assessing hormonal needs and determining individual doses. There are no data to reliably support these claims. <2+>

Bioidentical compounded hormone therapy offers no proven advantages over similar regulated products and lacks the protection to the patient offered by strict regulation and oversight. The hormones available in these preparations are all available in safe regulated products. All mainstream scientific, clinical and regulatory bodies in women’s health advise against the use of these products3–7. A prescriber of these products is at risk of future medicolegal claims.

Key messages

- Prescribing of compounded BHT is not recommended due to the lack of quality control and regulatory oversight associated with these products, together with lack of evidence of safety and efficacy. [B]
- The use of serum or salivary hormone levels is not recommended to assist in the management of MHT as these levels are of little value in selecting initial medication doses or in monitoring efficacy. [B]
- Women requesting compounded BHT should be encouraged to consider regulated products containing hormones which are structurally identical to those produced in the body. These are available in a wide range of doses and delivery methods. [B]

Vasomotor symptoms: pharmacologic treatments

The mechanisms underlying vasomotor symptoms (VMS) are still not well understood. Treatment of VMS without hormones is possible and may be the sole option in women with contraindications to estrogen or progesterone therapy. A variety of pharmacological agents decrease the frequency and intensity of hot flushes; however, head-to-head comparisons with hormone therapy or between non-hormonal agents are limited. Each pharmacological strategy has specific side-effects.

Within the drugs that have established alleviating actions on VMS are selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), some antiepileptic drugs, and other centrally acting drugs. While each of these categories of drugs is effective in clinical trials, there have been very few head-to-head studies of non-hormonal agents for the treatment of hot flushes1–4. <1++>

Efficacy of several SSRIs, SNRIs and gabapentin has been demonstrated in placebo-controlled trials5–14. <1++>

All clinical studies on agents targeting VMS are characterized by a relevant placebo effect, which can per se reduce hot flushes by up to 50%. <1++>

Information on the comparative effects of non-hormonal preparations versus estrogen therapy is limited to gabapentin and venlafaxine. High doses of gabapentin
(300 mg three times per day) have been shown to reduce hot flushes similar to 0.625 mg estrogen. However, at this dose gabapentin is associated with significant side-effects. Venlafaxine (75 mg/day) has also been shown to decrease hot flushes similar to a low dose of oral estradiol (0.5 mg) in a randomized trial. A head-to-head study found that venlafaxine (37.5 mg per day increasing to 75 mg controlled release) is equally effective but better tolerated than gabapentin (300 mg once per day increasing to 300 mg three times per day) in breast cancer patients. Both products reduced the frequency and severity of hot flushes (by 66%) but side-effects were greater with gabapentin. Gabapentin may be specifically useful in patients experiencing night-time flushes with nocturnal sweats and repeated awakenings, due to its sedating effect. Intake of a single dose of gabapentin at bedtime has been suggested in these patients and this treatment schedule may help decrease side-effects.

Comparisons of trials of venlafaxine, desvenlafaxine, paroxetine, citalopram, and escitalopram suggest that these molecules have similar efficacy on hot flushes. Sertraline and fluoxetine are not associated with significant reductions in hot flushes in placebo-controlled studies, and are therefore not recommended for treatment of VMS.

Clonidine, an α-2 adrenergic agonist, is slightly more effective than placebo in reducing hot flushes in a meta-analysis of ten trials. Clonidine use is associated with significant side-effects (dry mouth, dizziness, constipation, hypotension and sedation) that limit its clinical use. Transdermal preparations may be superior to oral ones due to more stable blood levels and may help increase compliance.

Women with a history of breast cancer represent an important category of patients where non-hormonal treatments are useful for the treatment of VMS. SSRIs/SNRIs decrease hot flushes up to 50% in these patients, and this is acceptable in most cases. Efficacy is similar in women taking tamoxifen. SSRIs inhibit the activity of CYP2D6, the enzyme that converts tamoxifen to its active metabolite, endoxifen. Paroxetine and fluoxetine are the strongest CYP2D6 inhibitors, while venlafaxine, desvenlafaxine, citalopram and escitalopram are less effective. Whether interference with CYP2D6 by SSRIs or SNRIs has any impact on breast cancer recurrence or survival is controversial, but this should be considered when selecting a treatment for hot flushes in these patients. If a SSRI/SNRIs is used, compounds that interfere less with tamoxifen metabolism, such as venlafaxine and citalopram, should be preferred. SSRIs do not interfere with the action of aromatase inhibitors and can be used safely in women receiving these drugs.

Duration of treatment of VMS with non-hormonal agents should be reviewed periodically, as with hormonal interventions. Initiation of treatment usually requires step-wise increases of dose to minimize side-effects. Similarly, discontinuation should be obtained by dose tapering over at least 2 weeks to avoid withdrawal symptoms.

**Key messages**
- Venlafaxine, desvenlafaxine, paroxetine, citalopram, and escitalopram are effective in reducing hot flushes in postmenopausal women.
- Paroxetine should be avoided in women receiving tamoxifen.
- Gabapentin is as effective but has more side-effects compared to SSRIs/SNRIs.

**Postmenopausal vulvovaginal atrophy**

After menopause, histological and functional changes in the vagina and urogenital epithelium appear due to a decline in estrogen levels and more than half of all postmenopausal women will experience symptoms associated with tissue atrophy.

A new definition for vulvovaginal atrophy (VVA) has been proposed by NAMS/ISSWSH. It has been named genitourinary syndrome of menopause (GSM), in order to describe more accurately the constellation of urogenital symptoms and signs associated with menopause and to remove the negative stigma of atrophy.

Women are poorly aware that VVA is a chronic condition with a significant impact on sexual health and quality of life and that effective and safe treatments may be available.

All local estrogen preparations (creams, pessaries, tablets, vaginal ring) are effective in decreasing signs and symptoms of vaginal atrophy but they differ slightly in their adverse-event profiles. Ospemifene, a SERM derived from toremifene, has also been shown to be effective in treating vulval and vaginal atrophy. Vaginal moisturizers and lubricants as well as regular sexual activity may be helpful to such women. Vaginal moisturizers may have an equivalent efficacy to topical vaginal estrogen and should be offered to women wishing to avoid the use of hormonal therapy.

**Key messages**
- Health-care providers should be proactive in order to help their patients to disclose the symptoms...
related to VVA and to seek adequate treatment when vaginal discomfort is clinically relevant. [B]

- Treatment should be started early, before irrevocable atrophic changes have occurred, and needs to be continued to maintain the benefits. [B]
- The principles of treatment in women with established VVA are both restoration of urogenital physiology and alleviation of symptoms; when VVA is the sole symptom, local estrogen treatment should be the first choice. [B]
- The choice of modality for local estrogen administration should be guided by patient preference. [D]
- Local estrogen therapy minimizes the degree of systemic absorption and, although vaginal administration can increase plasma levels of estrogens during chronic administration, the observed levels are not above the normal range of ≤ 20 pg/ml for postmenopausal women. [B]
- Additional progestogen is not indicated when appropriate low-dose, local estrogen is used, although long-term data (more than 1 year) are lacking. [B]
- If estrogen is ineffective or undesired, vaginal lubricants and moisturizers can relieve symptoms due to dryness, and sexual activity should be recommended on a regular basis. [C]
- There are few data on the use of vaginal estrogens in women with gynecological hormone-responsive cancers so they should be used with discretion. [D]
- Use of local estrogen in women on tamoxifen or aromatase inhibitors needs careful counselling and discussion with the patient and the oncology team. [D]
- Estriol and testosterone preparations may be an option for such patients but more studies are needed. [C]

**Novel menopause therapies**

**Urogenital**

Daily topical use of DHEA is promising in the treatment of VVA and sexual associated symptoms, due to a favorable safety profile in women with contraindications to MHT¹. Efficacy appears to be lost with twice-weekly maintenance administration². <1+++>

Ospemifene, a SERM recently approved at the dose of 60 mg orally, is indicated for the systemic treatment of moderate to severe dyspareunia associated with VVA in women who are unable to tolerate or unwilling to take local or systemic estrogens³. <1+++> A positive cascade effect on other domains of sexual function has been documented. Another SERM, lasofoxifene, is under investigation.

**Systemic**

A CEE 0.45 mg/bazedoxifene 20 mg combination product (tissue selective estrogen complex) has recently been approved for the management of VMS⁴. <1+++> This is potentially a useful option in women who are intolerant to the effects of progestogens. The combination lead to reduced breast density but further data are required to confirm its impact on breast cancer incidence⁵.

**Influence of methodology and epidemiology on MHT perception**

There is a hierarchy of scientific evidence that should be taken into account when drawing conclusions from any scientific investigation. In general (from the highest standard or level of evidence to the lowest), the standards of evidence are replicated findings from high-quality RCTs, RCTs of lesser quality, cohort studies, other observational studies such as repeated cross-sectional samples, case–control studies, case series and case reports, and, lastly, expert opinion. However, even RCTs and cohort studies must be interpreted with caution, particularly with reference to MHT (see Table 1).

Observational studies (e.g. Nurses’ Health Study) are primarily used for hypothesis generation and cannot demonstrate causality. Inherent biases in many observational studies of MHT typically include: selection bias – healthier women prescribed MHT; recall bias – recall of prior hormone usage may be influenced by later outcomes; prevention bias – monitoring and treating more intensively in women prescribed MHT; compliance bias – patients with greater adherence (even to placebo) have better outcomes; survivor bias – MHT may be stopped due to illness; prevalence-incidence bias – early adverse effects of MHT may not be observed if the user dies before becoming part of cohort.

RCTs (e.g. the WHI) are primarily used for hypothesis testing, to prove or disprove cause and effect. They can be downgraded in their level of evidence due to factors such as: poor compliance, dropout rate exceeding that accounted for in the study design, loss of blinding, deviation from protocol, inappropriate generalization of a single treatment to an entire class of treatments, and inappropriate generalization of results to groups for which the trial was inadequately powered. The WHI was

---

**Table 4. World Health Organization Council for International Organizations of Medical Sciences (CIOMS) classification of the frequency of drug reactions.**

<table>
<thead>
<tr>
<th>Frequency</th>
<th>CIOMS Classification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Very common</td>
<td>&gt; 1/10 (&gt; 10%)</td>
</tr>
<tr>
<td>Common (frequent)</td>
<td>&gt; 1/100 and &lt; 1/10 (&gt; 1% and &lt; 10%)</td>
</tr>
<tr>
<td>Uncommon (infrequent)</td>
<td>&gt; 1/1000 and &lt; 1/100 (&gt;0.1% and &lt; 1%)</td>
</tr>
<tr>
<td>Rare</td>
<td>&gt; 1/10 000 and &lt; 1/1000 (&gt;0.01% and &lt; 0.1%)</td>
</tr>
<tr>
<td>Very rare</td>
<td>&lt; 1/10 000 (&lt;0.01%)</td>
</tr>
</tbody>
</table>
designed to test the outcomes associated with use of MHT in women more than a decade past menopause. Its results have been generalized to women near menopause who were not adequately represented, and for whom some WHI findings suggested important contrasts with benefit at younger ages. Similarly, the WHI tested only one form of oral estrogen and one form of oral progestogen. Generalization of those results to other doses, other compounds and other routes of administration strays beyond the bounds of proper methodology, all the more so when evidence from other study designs, spanning from histological, to metabolic, to cohort, suggests meaningful differences by dose, compound and route of administration.

The World Health Organization Council for International Organizations of Medical Sciences (CIOMS) has classified the frequency of drug reactions, which would include the impact of MHT or estrogen therapy (see Table 4). However, these frequencies do not necessarily correspond to statistical significance. Rare findings in large RCTs and observational studies may be statistically significant because of the large sample size, but may be of minor clinical importance in their application to a particular patient in the clinical setting. Failure to provide a clinical context is often a problem in understanding and interpreting study outcomes.

Conclusions and action points

These IMS evidence-based recommendations are intended to encourage optimal care of all women in midlife and beyond. With a rapidly growing population of women in midlife and beyond, it is imperative that further research continues in midlife women to optimize quality of life and long-term well-being.

The key principles to achieve this goal are as follows:

- The benefits and risks of MHT vary greatly in individual circumstances.
- Research over the last decade has shown that risks can be minimized and benefits maximized with selection of the optimal regimen at the optimal time.
- The safety of MHT largely depends on age and time since menopause.
- Healthy women younger than 60 years should not be unduly concerned about the safety profile of MHT.
- New data and re-analyses of older studies by women’s age show that, for most women, the potential benefits of MHT given for a clear indication are many and the risks are few when initiated within a few years of menopause.
- Studies strongly suggest that it is the progestogen component of MHT that is more significant in any increase in breast cancer risk rather than the estrogen.
- Modern progestogens, natural progesterone and SERMs optimize metabolic and breast effects.
- Recent randomized trials such as the Danish Osteoporosis Prevention Study (DOPS) and studies using surrogate endpoints for long-term morbidities such as the Kronos Early Estrogen Prevention Study (KEEPS) and the Early versus Late Intervention Trial with Estradiol (ELITE) are now confirming the window of opportunity in early menopause when cardiovascular harm is avoided and benefits can be achieved.
- Increasing data indicate benefits for primary prevention of osteoporotic fractures and coronary artery disease and a reduction in all-cause mortality for women who initiate MHT around the time of menopause.

Key action points

- Health Departments/Regulators: Encourage change of policy towards menopause and MHT.
- The Prescribers: Expand education and training for health-care professionals to optimize menopause management.
- Media: Engage positively highlighting favorable data and putting risks into perspective.
- Pharma Industry: Reverse negative commercial/R&D decisions and encourage the exploration and development of novel regimens.
- The menopausal woman: Improve access to information to allow informed choice and increase proactive confidence to maintain menopausal health.
- MHT: Clarification of differences in action/risk profiles to maximize benefits and minimize adverse effects.

The Writing Group for the Recommendations

A summary of Declarations of interest in the past 2 years is listed below. A more detailed list is available on the IMS website.

R. J. Baber
Obstetrics and Gynaecology, Sydney Medical School North, The University of Sydney, Sydney, Australia
Advisory Board and/or Consultant: Pfizer
Speaker’s Bureau: Abbott

N. Panay
Imperial College London, UK, Co-Editor-in-Chief, Climacteric
Advisory Board and/or Consultant: Abbott, Bayer, Besins, Novo Nordisk, Pfizer, Shionogi
Speaker’s Bureau: Abbott, Bayer, Besins, Novo Nordisk

**A. Fenton**
Christchurch Women’s Hospital, Christchurch, New Zealand,
Co-Editor-in-Chief, Climacteric
Advisory Board and/or Consultant: Pfizer
Speaker’s Bureau: Besins, Mylan

**L. Cardozo**
Professor of Urogynaecology, King’s College Hospital, London, UK
Advisory Board and/or Consultant: Astellas, BMR, Golin Health
Speaker’s Bureau: Allergan, Astellas
Grant/research support: Pfizer

**C. Castelo-Branco**
Clinic Institute of Gynecology, Obstetrics and Neonatology,
Faculty of Medicine, University of Barcelona, Barcelona, Spain
Advisory Board and/or Consultant: Pierre Fabre, Shionogi
Speaker’s Bureau: Amgen, Isdin, Pfizer, Pierre Fabre, Shionogi

**S. R. Davis**
Women’s Health Research Program, Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia
Advisory Board and/or Consultant: AbbVie International, Pfizer, Agera Pharmaceuticals
Grant/research support: Lawley Pharmaceuticals

**T. J. de Villiers**
MediClinic Panorama and Department of Obstetrics and Gynecology, Stellenbosch University, Cape Town, South Africa
Advisory Board and/or Consultant: Adcock Ingram Ltd, Merck, Pfizer
Speaker’s Bureau: Adcock Ingram Ltd, Pfizer

**S. R. Goldstein**
Department of Obstetrics and Gynecology, New York University School of Medicine, New York, NY, USA
Advisory Board and/or Consultant: Abbvie, Amgen, Cook ObGyn, JDS Therapeutics, Pfizer, Radius Health Inc, Sermonix Pharmaceuticals, Shionogi Ltd
Speaker’s Bureau: JDS Therapeutics, Pfizer and Shionogi
Equipment loan as a consultant: Philips Ultrasound

**A. Gompel**
UF de Gynécologie, Université Paris Descartes, AP-HP, Hopitaux Paris Centre, Port Royal Cochin, INSERM U1007, Paris, France
No relevant financial relationships

**V. W. Henderson**
Departments of Health Research & Policy (Epidemiology) and of Neurology & Neurological Sciences, Stanford University, Stanford, CA, USA
Grant/research support: NIH
Travel reimbursement: American Academy of Neurology, International Menopause Society to participate in meetings of society committees

**H. N. Hodis**
Atherosclerosis Research Unit, Division of Cardiovascular Medicine, Keck School of Medicine, University of Southern California, USA

Grant/research support: NIH as Principal investigator

**R. D. Langer**
Associate Dean for Clinical and Translational Research and Professor of Family Medicine-Las Vegas, University of Nevada School of Medicine, Las Vegas, NV, USA
Litigation consultant: Roche Pharmaceuticals

**R. A. Lobo**
Department of Obstetrics and Gynecology, Columbia University, New York, NY, USA
Speaker’s Bureau: Pfizer
Grant/research support: Therapeutics MD

**P. M. Maki**
Departments of Psychiatry and Psychology, University of Illinois at Chicago, USA
Speaker’s Bureau: Abbott, Noven

**A. O. Mueck**
Department of Women’s Health, Germany and Capital Medical University, Beijing OB/GYN Hospital, WHO Centre, China
No relevant financial relationships

**R. E. Nappi**
Research Center for Reproductive Medicine, Gynecological Endocrinology and Menopause, IRCCS S. Matteo Foundation, University of Pavia, Pavia, Italy
Advisory Board and/or Consultant: Bayer HealthCare, Gedeon Richter, Merck Sharpe & Dohme, Shionogi Ltd
Speaker’s Bureau: Novo Nordisk, Pfizer, Shionogi Ltd, TEVA Women’s Health Inc
Grant/research support: Bayer HealthCare

**A. Pines**
Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
No relevant financial relationships

**G. Plu-Bureau**
Department of Gynecology, Hopitaux Universitaires Paris Centre, Paris Descartes University, Paris, France
No relevant financial relationships

**D. Robinson**
Department of Urogynaecology, King’s College Hospital, London, UK
Advisory Board and/or Consultant: Astellas, Pfizer, Allergan, Ferring
Speaker’s Bureau: Astellas, Pfizer, Allergan
Grant/research support: Astellas, Pfizer, Allergan

**T. Simoncini**
Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
Advisory Board and/or Consultant: Abbott, Actavis
Speaker’s Bureau: Abbott, Actavis

**S. Z. Vujovic**
Medical Faculty, University of Belgrade and Clinic of Endocrinology, Diabetes and Diseases of Metabolism, Clinical Center of Serbia, Belgrade, Serbia
No relevant financial relationships

**Source of funding** The costs of writing this paper have been supported entirely from the funds of the International Menopause Society.
References

Methodology


Mid-life body changes

15. Rogers NH, Perfield JW 2nd, Strissel KJ, Obin MS, Greenberg AS. Reduced energy expenditure and increased inflammation are early events in the development of ovariectomy-induced obesity. Endocrinology 2009;150:2161–8
22. Sorensen MB, Rosenfalck AM, Højgaard L, Ottesen B. Obesity and sarcopenia after menopause are reversed by sex hormone replacement therapy. Obes Res 2001;9:622–6

Diagnosis of menopause

4. Greenberg AS. Reduced energy expenditure and increased inflammation are early events in the development of ovariectomy-induced obesity. Endocrinology 2009;150:2161–8


**Premature ovarian insufficiency**


**Lifestyle, diet and exercise**


**Urogyneiology**


Postmenopausal osteoporosis


Skin, cartilage, connective tissues


Cardiovascular disease


15. Hodis HN. ELITE – Does the trial outcome confirm or refute the timing hypothesis of hormone therapy? Presented at the 14th World Congress on Menopause, May 1–4, 2014, Cancun, Mexico


Stroke


2. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the
Coagulation, venous thromboembolism disease and MHT


Central nervous system

6. Resnick SM, Maki PM, Rapp SR, et al. Effects of combination estrogen plus progestin hormone treatment on...
cognition and affect. J Clin Endocrinol Metab 2006;91:1802–10

Breast cancer


Ovarian cancer

Lung cancer

Upper gastrointestinal cancers

**General and sexual quality of life in the menopause**

1. Lindau ST, Gavrilova N. Sex, health, and years of sexually active life gained due to good health: Evidence from two US population based cross sectional surveys of ageing. BMJ 2010;340:c810

**Androgen therapy for perimenopausal and postmenopausal women**

5. Randolph JF Jr, Zheng H, Avis NE, Greendale GA, Harlow SD. Masturbation frequency and sexual function domains are associated with serum reproductive hormone levels across the menopausal transition. J Clin Endocrinol Metab 2015;100:258–66
8. Davis SR, Papalia MA, Norman RJ, et al. Safety and efficacy of a testosterone metered-dose transdermal spray for...

**Complementary therapies**

10. Chiu HY, Pan CH, Shyu YK, Han BC, Tsai PS. Effects of acupuncture on menopause-related symptoms and quality of life in women in natural menopause: a meta-analysis


Bioidentical hormone therapy


Vasomotor symptoms: MHT and pharmacologic treatments


24. Kelly CM, Juurlink DN, Gomes T, et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women...


Postmenopausal vulvovaginal atrophy


4. Archer DF. Efficacy and tolerability of local estrogen therapy for urogenital atrophy. Menopause 2010;17:194–203


Novel menopause therapies


